1 Macrophages only sense infectious SARS - CoV - 2 when they express sufficient ACE2 to 1 permit viral entry , where rapid cytokine responses then limit viral replication . 2 3 Larisa I Labzin 1 , 2 , 3 * , Keng Yih Chew 4 , Kathrin Eschke 1 , Xiaohui Wang 1 , 2 , Tyron Esposito 1 , 2 , 4 Claudia J Stocks 1 , 2 , James Rae 1 , 9 , Ralph Patrick 1 , Helen Mostafavi 1 , Brittany Hill 1 , Teodor E . 5 Yordanov 1 , Caroline L Holley 1 , 2 , Stefan Emming 1 , 2 , Svenja Fritzlar 5 , Francesca L . Mordant 5 , 6 Daniel P . Steinfort 6 , 7 , Kanta Subbarao 5 , 8 , Christian M . Nefzger 1 , Anne K Lagendijk 1 , Emma 7 Gordon 1 , Robert Parton 1 , 9 , Kirsty R . Short 3 , 4 , Sarah L . Londrigan 5 , # , Kate Schroder 1 , 2 , 3 , 4 , # . 8 9 # These authors contributed equally 10 * Correspondence should be addressed to l . labzin @ uq . edu . au 11 12 1 Institute for Molecular Bioscience ( IMB ) , The University of Queensland , Brisbane , QLD , 13 Australia 14 2 IMB Centre for Inflammation and Disease Research , The University of Queensland , 15 Brisbane , QLD , Australia 16 3 Australian Infectious Diseases Research Centre , The University of Queensland , Brisbane , 17 QLD , Australia 18 4 School of Chemistry and Molecular Biosciences , The University of Queensland , Brisbane , 19 QLD , Australia 20 5 Dept of Microbiology and Immunology , The University of Melbourne at the Peter Doherty 21 Institute for Infection and Immunity , Melbourne , Victoria , Australia . 22 6 Department of Medicine , The University of Melbourne , Parkville , Victoria , Australia 23 7 Department of Respiratory Medicine , Royal Melbourne Hospital , Parkville , Victoria , 24 Australia 25 8 WHO Collaborating Centre for Reference and Research on Influenza , Victorian Infectious 26 Diseases Reference Laboratory , at The Peter Doherty Institute for Infection and Immunity , 27 Melbourne , Victoria , Australia . 28 9 Centre for Microscopy and Microanalysis , The University of Queensland , Brisbane , QLD , 29 Australia 30 31 32 33 34 2 Abstract 35 36 Macrophages are key cellular contributors to COVID - 19 pathogenesis . Whether SARS - CoV - 37 2 can enter macrophages , replicate and release new viral progeny remains controversial . 38 Similarly , whether macrophages need to sense replicating virus to drive cytokine release is 39 also unclear . Macrophages are heterogeneous cells poised to respond to their local 40 microenvironment , and accordingly , the SARS - CoV - 2 entry receptor ACE2 is only present 41 on a subset of macrophages at sites of human infection . Here , we use in vitro approaches to 42 investigate how SARS - CoV - 2 interacts with ACE2 - negative and ACE2 - positive human 43 macrophages and determine how these macrophage populations sense and respond to SARS - 44 CoV - 2 . We show that SARS - CoV - 2 does not replicate within ACE2 - negative human 45 macrophages and does not induce pro - inflammatory cytokine expression . By contrast , ACE2 46 expression in human macrophages permits SARS - CoV - 2 entry , replication , and virion 47 release . ACE2 - expressing macrophages sense replicating virus to trigger pro - inflammatory 48 and anti - viral programs that limit virus release . These combined findings resolve several 49 controversies regarding macrophage - SARS - CoV - 2 interactions and identify a signaling 50 circuit by which macrophages sense SARS - CoV - 2 cell entry and respond by restricting viral 51 replication . 52 53 54 One sentence summary : 55 56 Lack of macrophage ACE2 expression precludes SARS - CoV - 2 entry and sensing , while 57 ACE2 - expressing macrophages sense intramacrophage SARS - CoV - 2 replication to induce 58 rapid anti - viral responses that limit new virion release . 59 60 3 Main Text 61 62 INTRODUCTION 63 64 Severe Acute Respiratory Syndrome Coronavirus 2 ( SARS - CoV - 2 ) , belonging to the 65 Coronaviridae family , is an enveloped , single - stranded RNA virus with a positive - sense 66 genome . Many human respiratory viruses , including SARS - CoV - 2 , infect epithelial cells 67 lining the upper and lower airways , resulting in productive replication and the release of 68 newly synthesized infectious viral particles . The virus Spike ( S ) glycoprotein facilitates entry 69 into target epithelial cells by binding to the surface - expressed angiotensin - converting enzyme 70 2 ( ACE2 ) receptor ( 1 ) . The well - characterized ACE2 - Spike interaction exposes a critical S 71 cleavage site ( S2 ) that can be cleaved by the host serine protease TMPRSS2 ( transmembrane 72 protease serine 2 ) , also expressed on the plasma membrane . This allows the fusion of the 73 viral and cellular membranes , followed by the release of viral RNA directly into the 74 cytoplasm ( reviewed in ( 2 ) and ( 3 ) ) . SARS - CoV - 2 , particularly omicron variants , can also 75 attach to ACE2 and enter cells via the endocytic pathway . Here , the S protein is cleaved by 76 endosomal proteases to allow fusion between the viral and endosomal membranes ( 4 ) . Host 77 cell ribosomes immediately translate the infecting , positive sense RNA genome into two 78 large polyproteins . These polyproteins are proteolytically processed to generate individual 79 viral proteins required for replication . New virions are assembled in the endoplasmic 80 reticulum and Golgi of the host cell , before secretion from the cell via exocytosis or through a 81 lysosomal egress pathway ( 3 ) . Our understanding of the SARS - CoV - 2 replication cycle 82 comes from studies in primary epithelial cells or epithelial cell lines . How this may differ in 83 other potentially susceptible cell types , including distinct macrophage populations , remains 84 unclear . 85 86 Effective host defense against infection relies on accurate and timely immune detection . 87 Accumulating evidence suggests that severe COVID - 19 results from a failure of early host - 88 interferon signaling to control SARS - CoV - 2 , followed by exacerbated pro - inflammatory 89 responses driving tissue damage . Airway epithelial cells , the primary target for SARS - CoV - 2 90 infection ( 5 ) , respond by releasing anti - viral and pro - inflammatory cytokines ( 6 , 7 ) . Airway - 91 resident or newly recruited macrophages also appear to be a key source of pro - inflammatory 92 cytokines in severe COVID - 19 ( 8 , 9 ) , with macrophage - derived cytokines implicated in the 93 severe pathology observed in patients ( 10 – 13 ) . 94 4 95 Macrophages are sentinel innate immune cells that defend the airways during respiratory 96 viral infection . Yet , and in contrast to epithelial cells , infection of human macrophages results 97 in an abortive replication cycle for many respiratory viruses ( including seasonal influenza A 98 viruses ( 14 ) and rhinovirus ( 15 ) ) , despite macrophages supporting the early stages of 99 infection ( entry and synthesis of new viral RNA and protein ) . Therefore , macrophages can 100 function as a viral ‘dead end’ to limit viral dissemination ( 16 ) and can sense infectious viral 101 particles , infected cells , and tissue damage to orchestrate anti - viral and pro - inflammatory 102 programs ( 17 – 19 ) . Single - cell RNA sequencing has revealed viral RNA within macrophage 103 populations in human COVID - 19 lungs ( 8 , 20 ) and ex vivo lung explants ( 21 ) . 104 Similarly , immunostaining of COVID - 19 autopsy lungs showed macrophages containing 105 viral antigens ( Spike and the RNA - dependent RNA polymerase : RdRp ) in situ ( 22 ) . Whether 106 SARS - CoV - 2 enters these macrophages via ACE2 remains unclear , as is the fate of 107 intramacrophage SARS - CoV - 2 . These in vivo studies did not ascertain if SARS - CoV - 2 108 productively replicates within macrophages to produce new viral RNA and protein leading to 109 new virion assembly , nor whether macrophages release newly synthesized infectious virions . 110 Further , previous studies did not elucidate whether SARS - CoV - 2 needs to enter and actively 111 replicate in macrophages to trigger macrophage anti - viral and pro - inflammatory responses . 112 113 In vitro models of SARS - CoV - 2 interactions with macrophages have focused on human 114 monocyte - derived macrophages ( HMDM ) . While there is consensus that HMDMs exposed to 115 SARS - CoV - 2 do not release newly - synthesized infectious virions ( 7 , 12 , 13 , 23 – 25 ) , some 116 studies report that HMDMs support the early stages of infection that include viral entry and 117 replication ( i . e . , viral RNA replication and protein synthesis ) ( 12 , 13 , 23 ) . In contrast , others 118 report that HMDM are refractory to SARS - CoV - 2 entry ( 7 , 25 ) . Accordingly , whether 119 SARS - CoV - 2 exposure induces HMDM pro - inflammatory and anti - viral signaling or 120 whether this requires active viral entry and replication is also controversial . Multiple reports 121 suggest that macrophage challenge with SARS - CoV2 triggers pro - inflammatory responses 122 ( 12 , 13 , 26 ) . In contrast , others report that SARS - CoV - 2 challenge does not activate 123 macrophage inflammatory functions , consistent with a lack of viral entry and the early stages 124 of viral replication ( 7 , 25 ) . 125 126 The current study investigates whether macrophage ACE2 expression dictates macrophage 127 susceptibility to SARS - CoV - 2 entry and replication and how this shapes macrophage 128 5 inflammatory responses . We found that SARS - CoV - 2 cannot enter or replicate within ACE2 - 129 negative macrophages , and these cells do not produce pro - inflammatory cytokines in 130 response to viral challenge . In contrast , macrophages engineered to ectopically express ACE2 131 support SARS - CoV - 2 entry , replication , and new virion release . ACE2 - expressing 132 macrophages sense newly synthesized viral RNA and induce pro - inflammatory and anti - viral 133 mediator expression . This rapid induction of anti - viral programs in ACE2 - expressing 134 macrophages limits ongoing virion release . Thus , we identify two blocks to SARS - CoV - 2 135 infection and replication in ACE2 - negative and - positive macrophages . ACE2 - negative 136 macrophages are refractory to SARS - CoV - 2 infectious entry and do not support the early 137 stages of replication . In contrast , ACE2 - positive macrophages are susceptible to the early 138 stages of infection and replication but mount a second post - entry block that constrains the 139 production and release of newly synthesized infectious virions . 140 141 RESULTS 142 143 In vitro models of ACE2 - positive and ACE2 - negative macrophages 144 145 Given that ACE2 is the primary receptor for SARS - CoV - 2 , we anticipated that ACE2 146 expression would determine the susceptibility and permissivity of macrophages to SARS - 147 CoV - 2 infection and replication . We reanalyzed published scRNA - seq lung data from three 148 studies ( 20 , 27 , 28 ) , representing two sets of control and two sets of COVID - 19 - infected 149 individuals . We aligned the datasets to a common cell type reference to study ACE2 mRNA 150 expression amongst myeloid cell types ( e . g . , infiltrating monocytes , monocyte - derived 151 macrophages , and resident alveolar macrophages ) . Less than 2 % of all cell types expressed 152 ACE2 mRNA , including alveolar epithelial AT1 and AT2 cells targeted by SARS - CoV - 2 153 ( fig . S1 ) . In control and COVID - 19 - infected lungs , a small proportion ( < 0 . 05 % ) of 154 monocyte - derived macrophages expressed ACE2 mRNA . Very few tissue - resident 155 macrophages and transitioning monocyte - derived macrophages expressed ACE2 mRNA in 156 control lungs , though this proportion increased in the COVID - 19 - infected lung . Monocytes 157 did not express ACE2 mRNA in either condition ( fig . S1 ) . These results are consistent with 158 published scRNA sequencing analyses on ACE2 mRNA expression across cell types ( 20 , 27 – 159 29 ) . A recent preprint reported ACE2 - positive macrophages in lung explants infected ex vivo , 160 as determined by immunofluorescence ( 30 ) . These data suggest that both ACE2 - positive and 161 ACE2 - negative macrophages are present in SARS - CoV - 2 - infected lungs . 162 6 163 We next assessed ACE2 expression in HMDM cultured from blood monocytes to determine 164 their suitability as an in vitro cell model for ACE2 - positive or ACE2 - negative macrophages . 165 Monitoring ACE2 mRNA and protein revealed low ACE2 mRNA expression in HMDM , and 166 undetectable levels of ACE2 protein ( Fig . 1A , B ) , even when HMDM were treated with 167 IFN β ( Fig . 1B ) . HMDM thus resemble ACE2 - negative macrophages in COVID - 19 lungs . 168 169 The lung - resident macrophage populations are immune sentinels of the airways , with distinct 170 origins and properties to HMDM ( 31 ) . Along with airway epithelial cells , airway 171 macrophages are prime targets for infection by many respiratory viruses . We thus 172 investigated the ACE2 expression status of this lung - resident macrophage population . We 173 utilized airway macrophages from bronchoalveolar lavage ( BAL ) as representative resident 174 lung macrophages and observed that their ACE2 protein expression was below detection 175 levels ( Fig . 1C ) . Together , this data indicates that HMDM and BAL macrophages cultured ex 176 vivo model ACE2 - negative macrophage populations in vivo . 177 178 To model ACE2 - positive cells , we used lentiviral transduction to ectopically express either 179 ACE2 ( untagged ) or a control protein ( mScarlet : mSc ) in the THP - 1 monocytic cell line prior 180 to their differentiation into macrophage - like cells with phorbol - myristate - acetate ( PMA ) . We 181 confirmed that ectopic ACE2 expression in THP - 1 cells yielded readily detectable ACE2 182 mRNA and protein ( Fig . 1A , 1B ) . The surface protease TMPRSS2 , which is required for S 183 protein cleavage , was also readily detected at the protein level in HMDM , THP - 1 - ACE2 , and 184 THP - 1 - mSc cells ( Fig . 1B ) , indicating its presence in both ACE2 - positive and ACE2 - 185 negative macrophages . 186 187 ACE2 - negative macrophages do not support SARS - CoV - 2 entry and replication 188 189 Despite the small proportion of ACE2 - positive macrophages at sites of human SARS - CoV - 2 190 infection ( ( 20 , 27 ) , fig S1 ) , many macrophages are positive for SARS - CoV - 2 RNA or protein 191 in vivo ( 8 , 20 , 22 ) , potentially reflecting an ACE2 - independent mechanism of viral entry into 192 macrophages . We thus investigated whether SARS - CoV - 2 can enter HMDMs , which do not 193 express ACE2 ( Fig . 1A , 1B ) . We left the viral inoculum on HMDM to maximize the uptake 194 of SARS - CoV - 2 virions . For these experiments , we included SARS - CoV - 2 - permissive Calu - 195 3 epithelial cells as a positive control for viral infection and replication . Calu - 3 cells were 196 7 susceptible to infection at high and low doses ( MOI 5 and 0 . 5 ) . We detected an increase in 197 cell - associated viral RNA between two hours ( indicative of input virus ) and 24 h post - 198 infection ( p . i . ) , indicating newly synthesized viral RNA and active replication ( Fig . 2A ) . 199 Consistent with productive infection in Calu - 3 cells , we also detected viral sub - genomic 200 RNA ( indicating new viral RNA synthesis ; Fig . S2A ) and newly synthesized viral 201 nucleoprotein ( NP , increased from two to 72 h ; Fig . 2B ) . In contrast , cell - associated viral 202 RNA levels did not rise over the same time course in HMDM infected with either MOI 203 dosage ( Fig . 2C ) . Viral sub - genomic RNA was barely detectable in HMDM ( Fig . S2B ) , and 204 while we could detect NP expression in HMDM at two hours p . i . , NP levels were barely 205 detectable 24 h p . i . ( Fig . 2D ) . These data indicate that HMDM are not susceptible to SARS - 206 CoV - 2 infection and do not support the early stages of viral replication , including the 207 production of newly synthesized viral RNA and protein . 208 209 We next tested whether BAL macrophages support ACE2 - independent viral entry and 210 replication by challenging these cells with SARS - CoV - 2 at an MOI of 1 . SARS - CoV - 2 - 211 challenged BAL macrophages showed no increase in cell - associated viral RNA ( indicative of 212 the early stages of virus replication ) between two and 48 h post - infection , in contrast to the 213 SARS - CoV - 2 - susceptible control cell line , VERO E6 ( Fig . 2E ) . An increase in viral RNA 214 isolated from cell - free VERO E6 supernatants between two and 48 h post - infection indicated 215 productive viral replication . However , we did not observe an increase in viral RNA in 216 supernatants of SARS - CoV - 2 infected BAL macrophages ( Fig . 2F ) . As for HMDM , these 217 data indicate that ACE2 - negative BAL macrophages are not permissive to the early stages of 218 SARS - CoV - 2 infection and replication . 219 220 ACE2 - positive macrophages support viral entry , replication , and new virion release 221 222 We next investigated whether ACE2 - positive macrophages could support SARS - CoV - 2 entry 223 and replication . We challenged THP - 1 - ACE2 ( Fig . 1A , 1B ) with SARS - CoV - 2 ( MOI 0 . 5 and 224 5 ) and compared viral replication and release to THP - 1 - mSc ( ACE2 - negative ) and Calu - 3 225 control cells . Cell - associated viral RNA significantly increased from 0 h ( input ) to 24 h p . i . 226 for both MOIs in THP - 1 - ACE2 cells before plateauing from 24 to 72 h p . i . , indicating cell 227 susceptibility and early - stage viral RNA replication ( Fig . 3A , 3B ) . By contrast , viral RNA 228 levels did not increase in the THP - 1 - mSc control cells at any time ( Fig . 3A , 3B ) , similar to 229 our observations in other ACE2 - negative macrophages ( HMDM and BAL ; Fig . 2C , 2E , 2F ) . 230 8 Calu - 3 cells support viral replication and virion release ( 32 ) ; accordingly , SARS - CoV - 2 231 RNA levels continued to rise over time ( Fig . 3A , 3B ) . Consistent with new viral protein 232 synthesis , we observed robust NP staining at 24 h post - infection in THP - 1 - ACE2 but not 233 THP - 1 - mSc cells ( Fig . 3C ) . Only 16 % of THP - 1 - ACE2 cells were NP positive at 24 h p . i . 234 ( Fig . 3D ) , indicating heterogeneity in the cellular response to SARS - CoV - 2 . 235 236 To determine whether the increase in cell - associated viral RNA levels in THP - 1 - ACE2 cells 237 was coupled to the release of infectious virus , we performed plaque assays on cell - free 238 supernatants between 0 h and 72 h p . i . At MOI 0 . 5 , we observed a significant increase in 239 infectious viral particles in the THP - 1 - ACE2 cell - free supernatants at 24 h p . i . , compared 240 with the levels of residual input virus ( 0 h p . i . ) , which is consistent with productive infection 241 ( Fig . 3E ) . We observed a similar increase in THP - 1 - ACE2 cells at 24 h p . i . using MOI 5 242 ( Fig . 3F ) . Control epithelial cells ( Calu - 3 : Fig . 3E , 3F , and A549 - ACE2 cells , Fig . S3 ) 243 supported productive virus release . As expected , there was no evidence of productive 244 replication in control THP - 1 - mSc cells at either MOI ( Fig . 3E , 3F ) , which is consistent with 245 a lack of susceptibility to infection ( Fig . 3A , 3B ) . This shows that ACE2 - expressing 246 macrophages support the initial stages of infection , new viral RNA synthesis , and assembly 247 and release of newly synthesized , infectious viral particles . 248 249 Macrophages can internalize SARS - CoV - 2 independently of ACE2 250 251 Additional SARS - CoV - 2 entry receptors beyond ACE2 are reported , including the C - type 252 lectin receptors ( CLRs ) ( 26 ) and CD169 ( 33 ) . Since our assays to measure viral protein and 253 RNA could not distinguish whether the virus is intracellular or extracellular ( Fig . 2C , 2D ) , we 254 next determined whether SARS - CoV - 2 can still bind and enter HMDM , despite the lack of 255 ACE2 expression . We used transmission electron microscopy to determine the sub - cellular 256 location of incoming virions , using a high MOI of 20 . HMDM ( Fig . 4A , B ) and THP - 1 - 257 ACE2 ( Fig . 4C ) displayed internalized , intact virions within the phagosomal system after one 258 hour of infection . The THP - 1 - ACE2 cells also showed virions bound to the plasma 259 membrane and possibly undergoing fusion ( Fig . 4D , E ) . These virions were morphologically 260 similar to the new structures released from Calu - 3 at 72 h p . i . ( Fig . 4F ) . Since THP - 1 - ACE2 261 cells endogenously express TMPRSS2 ( Fig . 1B ) , this suggests that THP - 1 - ACE2 cells 262 support viral fusion at the plasma membrane to deliver the viral genome and NP directly into 263 the cytoplasm . Together , these results indicate that while HMDM take up SARS - CoV - 2 into 264 9 phagosomal compartments , low ACE2 expression will preclude SARS - CoV - 2 S processing 265 and virus - cell membrane fusion , necessary steps for this virus to enter the cytoplasm . 266 267 ACE2 - negative macrophages do not release pro - inflammatory cytokines or anti - viral 268 mediators upon SARS - CoV - 2 exposure 269 270 Macrophages express a suite of pattern recognition receptors ( PRRs ) at strategic subcellular 271 locations to detect microbial challenges . PRRs can sense viral RNA and proteins incorporated 272 in incoming virions and RNA and proteins synthesized during viral replication ( 34 – 36 ) . We 273 detected viral particles in HMDM phagosomal compartments at one - hour p . i . ( Fig . 4B ) , and 274 so we next assessed whether ACE2 - negative macrophages could sense incoming virions from 275 these compartments . We challenged HMDM with high dose SARS - CoV - 2 ( MOI 5 ) for 24 h 276 without removing the virus to allow maximal macrophage responses . SARS - CoV - 2 did not 277 trigger cytokine ( C - X - C motif chemokine ligand 10 : CXCL10 ; Interleukin - 6 : IL - 6 ; or Tumor 278 Necrosis Factor : TNF ) release in vitro ( Fig . 5A ) , despite reports of high circulating levels of 279 these cytokines during human SARS - CoV - 2 infection ( 37 , 38 ) . By contrast , HMDM showed 280 a robust secretory response to synthetic viral mimetics such as the toll - like receptor ( TLR ) 281 7 / 8 ligand , R848 ( TNF , IL - 6 ) , and the melanoma differentiation - associated protein 5 282 ( MDA5 ) ligand , transfected poly I : C ( pIC ) ( CXCL10 ) ( Fig . 5A ) . mRNA analyses revealed 283 that SARS - CoV - 2 did not provoke HMDM expression of IFNB1 , IFNL1 , CXCL10 , IL6 , 284 TNF , or IL1B at two or 24 h p . i . , at either low ( 0 . 5 ) or high ( 5 ) MOI ( Fig . 5B ) . R848 and pIC 285 stimulation robustly induced these genes , indicating that the HMDM were signaling 286 competent ( Fig . 5B ) . Thus , HMDMs do not respond to SARS - CoV - 2 exposure in vitro , even 287 at the high MOI of 5 or when virions are present in the phagosomal system . 288 289 ACE2 - positive cells sense replicating SARS - CoV - 2 to trigger pro - inflammatory and 290 anti - viral responses 291 292 Since ectopic ACE2 expression in macrophages permits efficient SARS - CoV - 2 entry and 293 early - stage viral replication , we examined whether THP - 1 - ACE2 cells produce pro - 294 inflammatory and anti - viral mediators upon SARS - CoV - 2 challenge . THP - 1 - ACE2 cells 295 strongly upregulated IFNB1 , IFNL1 , CXCL10 , and IL6 mRNA expression after infection with 296 SARS - CoV - 2 for 24 h ( at MOI 5 , Fig . 6A ; or MOI 0 . 5 , fig . S4A ) , correlating with increased 297 SARS - CoV - 2 viral RNA levels ( Fig . 3A - B ) . In contrast , THP - 1 - mSc cells did not respond to 298 10 SARS - CoV - 2 challenge at either MOI ( Fig . 6A , fig . S4A ) , like HMDM ( Fig . 5A , 5B ) . 299 SARS - CoV - 2 infection downregulated IL1B mRNA levels in THP - 1 - ACE2 cells but not in 300 THP - 1 - mSc cells ( Fig . 6B , fig . S4A ) , likely due to negative regulation of IL1B mRNA 301 expression by interferons ( 39 ) . Viral sensing pathways were operational in THP - 1 - ACE2 and 302 THP - 1 - mSc cells , as both cell types responded equally to MDA5 stimulation via pIC 303 transfection , including robustly downregulating IL1B mRNA expression ( fig . S4B ) . In Calu - 3 304 cells , anti - viral ( IFNB1 , IFNL1 , CXCL10 ) and pro - inflammatory ( TNF , IL6 ) gene induction 305 peaked at 72 h p . i . ( at MOI 5 , Fig . 6C ; MOI 0 . 5 , fig . S4C ) , consistent with published 306 observations ( 7 ) and the rise in SARS - CoV - 2 viral RNA expression ( Fig . 3A , B ) and 307 productive virus release ( Fig . 3E , F ) . To determine whether THP - 1 - ACE2 cells responded to 308 incoming versus replicating virus , we treated cells with the RdRp inhibitor remdesivir ( 40 ) . 309 Remdesivir ablated viral replication ( Fig . 6D ) and the ensuing induction of IFNB1 , IFNL1 , 310 and IL6 ( Fig . 6E ) . Intriguingly , remdesivir did not modulate CXCL10 expression during 311 infection at MOI 5 ( Fig . 6E ) . This suggests that incoming virions may also be sensed and 312 trigger distinct inflammatory responses compared with replicating virions . Collectively , 313 these data indicate that ACE2 - positive macrophages are poised to sense entry and early - stage 314 viral replication and respond by mounting potent anti - viral programs . 315 316 Blocking cytokine signaling in ACE2 - positive cells prolongs productive virion release 317 318 Recent studies suggest that host cell death curbs the release of SARS - CoV - 2 infectious 319 virions ( 41 ) . We next explored whether the death of THP - 1 - ACE2 cells was responsible for 320 the decline in viral titers at 48h and 72h p . i . ( Fig . 3E , 3F ) . Indeed , virus - challenged THP - 1 - 321 ACE2 cells showed a modest but significant decrease ( ~ 20 % ) in viability compared to THP - 322 1 - mSc cells at 72 h p . i . ( Fig . 7A ) . Thus , cell death may limit virus release from THP - 1 - ACE2 323 challenged with high viral loads . 324 325 We also noted that the rapid and robust induction of type I and III interferons in THP - 1 - 326 ACE2 cells peaked at 24 h p . i . , much earlier than in Calu - 3 cells ( Fig . 6A , 6B ) . Interferons 327 provide autocrine and paracrine signals to activate an anti - viral state through the induction of 328 interferon - stimulated genes , which act as restriction factors to limit viral infection ( 42 ) . 329 Indeed , type I IFN aborts influenza A virus infection in murine macrophages ( 16 ) . We thus 330 hypothesized that interferon signaling in THP - 1 - ACE2 cells induces host factors that impede 331 viral replication , limiting the release of productive virions . In contrast , the delayed induction 332 11 of IFNB1 and IFNL1 in Calu - 3 cells , potentially through viral antagonism , may contribute to 333 ongoing viral replication and release at 48 and 72 h p . i . ( Fig . 3E , 3F ) . We tested this 334 hypothesis using a TBK1 inhibitor ( BX - 795 ) to block virus - induced interferon induction and 335 signaling ( 43 ) in THP - 1 - ACE2 cells ( Fig . 7B ) . As expected , BX - 795 suppressed pIC - induced 336 expression of IFNB1 , IFNL1 , and the interferon - stimulated gene CXCL10 ( fig . S5 ) . We next 337 challenged THP - 1 - ACE2 and Calu - 3 cells with SARS - CoV - 2 for 72 h in the presence and 338 absence of BX - 795 . BX - 795 suppressed SARS - CoV - 2 - induced CXCL10 production from 339 THP - 1 - ACE2 cells ( Fig . 7C ) , significantly increasing viral release at 72h p . i . ( Fig . 7D ) . BX - 340 795 did not boost the release of productive virions from Calu - 3 cells ( Fig . 7E ) , consistent 341 with published observations ( 7 ) . These findings indicate that even though SARS - CoV - 2 can 342 enter ACE2 - positive macrophages , rapid anti - viral signaling limits viral replication and 343 release . 344 345 DISCUSSION 346 347 A key question in SARS - CoV - 2 pathogenesis is which type of host cells efficiently sense 348 SARS - CoV - 2 to trigger inflammatory cytokine and anti - viral mediator release . Since 349 macrophages are prime candidates for sensing and responding to SARS - CoV - 2 ( 11 ) , a second 350 unresolved question is whether SARS - CoV - 2 can infect and productively replicate in human 351 macrophages . This study identifies ACE2 as a critical determinant of macrophage 352 susceptibility to infection and sensing of infectious SARS - CoV - 2 . 353 354 We demonstrate here that HMDM do not express ACE2 and are thus suitable in vitro models 355 for ACE2 - negative macrophages . While HMDMs phagocytose virus , they do not permit 356 early - stage viral replication or protein synthesis and do not sense phagocytosed virus to 357 trigger inflammatory responses . Our observation that SARS - CoV - 2 does not replicate in 358 HMDM or BAL is consistent with multiple reports of abortive SARS - CoV - 2 infection of 359 macrophages in vitro ( 12 , 13 , 23 , 24 ) . While these studies demonstrate that macrophage viral 360 challenge results in decreasing viral RNA ( 12 , 13 , 23 ) and viral protein ( 24 ) levels , and 361 macrophages fail to produce new infectious virus ( 12 , 23 ) , these reports nevertheless observe 362 virus entry into macrophages via quantification of SARS - CoV - 2 nucleoprotein - positive cells . 363 This contrasts with studies reporting no viral entry into HMDM ( 7 , 25 ) . We observe virions 364 within phagosomes ( Fig . 4B ) , indicating that SARS - CoV - 2 virions can enter the macrophage 365 phagolysosomal system . Despite this , we propose that the virus does not enter the HMDM 366 12 cytoplasm , likely because , without ACE2 , the Spike protein does not undergo the necessary 367 conformational changes for membrane fusion . 368 369 ACE2 expression analysis across cell types in healthy and COVID - 19 lungs shows that a 370 small proportion of macrophages express ACE2 , corroborating new reports that both ACE2 - 371 positive and - negative macrophages are likely to be present at sites of infection in vivo ( 20 , 372 27 , 29 ) . Age , sex , and co - morbidities may influence cellular ACE2 expression ( 44 ) , as well 373 as environmental cues such as hypoxia within tissues ( 45 , 46 ) . How macrophage ACE2 374 expression is regulated has yet to be elucidated . Uncovering the macrophage - specific cues 375 and pathways regulating ACE2 expression and function will yield further insight into how 376 ACE2 - positive macrophages can be detected and targeted . 377 378 In line with our findings herein , other non - epithelial cells that do not usually express ACE2 , 379 such as endothelial cells , are rendered susceptible and permissive to productive SARS - CoV - 2 380 infection by ectopic ACE2 expression ( 32 ) . In THP - 1 cells , ectopic ACE2 expression 381 facilitated SARS - CoV - 2 entry and early - stage replication , but in response , these cells 382 initiated an interferon program that limits new virion release after 24h p . i . ( Fig . 3E , 3F , 6A ) . 383 This limit could reflect the death of infected macrophages , as observed for antibody - 384 dependent monocyte infection ( 47 ) , or restriction by macrophage anti - viral programs . While 385 we observe some virus - induced cell death in ACE2 - positive macrophages ( Fig . 7A ) , our 386 TBK1 inhibitor experiments ( Fig . s 7C - D ) indicate that a potent macrophage anti - viral 387 response interrupts the viral replication cycle . Future studies should elucidate the precise anti - 388 viral programs underpinning macrophage restriction of SARS - CoV - 2 . Nevertheless , our 389 findings suggest that ACE2 - positive macrophages induce a sufficiently robust anti - viral 390 response to prevent them from acting as ‘Trojan horses’ to disseminate SARS - CoV - 2 to 391 extra - respiratory tissues . If such anti - viral signaling programs are compromised , such as in 392 patients with inborn errors of immunity or circulating IFN autoantibodies ( 48 , 49 ) , then 393 ACE2 - positive macrophages may substantially contribute to increased viral loads and viral 394 dissemination . 395 396 The proportion of macrophages positive for viral RNA in COVID - 19 lungs is much higher 397 than that of ACE2 - positive macrophages ( 20 , 50 , 51 ) . Our data suggest that this is not due to 398 ACE2 - independent SARS - CoV - 2 entry into and replication within macrophages , in contrast 399 to a recent study that reported CD169 - dependent , ACE2 - independent macrophage 400 13 infection ( 33 ) . Instead , we expect macrophages positive for viral RNA may be ACE2 - negative 401 macrophages with phagocytosed virions ( Fig . 4B ) , extracellular viral RNA , or virus - infected 402 cells ( 52 ) . Alternatively , ACE - negative macrophages might be infected via an antibody - 403 dependent uptake route , as recently shown for SARS - CoV - 2 - infected human monocytes ( 47 ) . 404 Our data show that the small proportion of macrophages positive for ACE2 can be directly 405 infected and trigger a distinct inflammatory response to ACE2 - negative macrophages 406 encountering SARS - CoV - 2 virions . Importantly , for ACE2 - positive macrophages , our data 407 suggest that the viral RNA present in macrophages in vivo also reflects limited productive 408 infection . A direct comparison of macrophage responses to these distinct routes of viral 409 uptake would elucidate whether targeting one subset could maintain protective anti - viral 410 responses while potentially limiting pathology . 411 412 The failure of primary HMDM to respond to SARS - CoV - 2 exposure ( Fig . 5A , 5B ) contrasts 413 with previous reports that SARS - CoV - 2 induces the expression of cytokine mRNAs 414 ( including IL6 , CXCL10 , and TNF ) in HMDM ( 12 , 13 , 26 , 53 ) . Typically , a virus must enter 415 and replicate within a cell to activate cytosolic PRRs ( so - called ‘cell intrinsic’ sensing ) , 416 concomitant with a high threat to that cell . Our data indicate that ACE2 - negative 417 macrophages do not respond directly to SARS - CoV - 2 exposure with cytokine production 418 ( Fig . 5A , 5B ) because lack of virus entry precludes ‘cell intrinsic’ sensing . Our results thus 419 agree with published observations that SARS - CoV - 2 does not trigger cytokine production 420 from HMDM ( 25 ) and that SARS - CoV - 2 also fails to trigger the interferon system in human 421 alveolar macrophages ( 24 ) . In contrast , ACE2 - positive macrophages detected actively 422 replicating SARS - CoV - 2 to trigger potent IFNB1 and IFNL1 induction ( Fig . 6E ) . We 423 hypothesize that the cytosolic viral sensors retinoic acid - inducible gene - 1 ( RIG - I ) and 424 MDA5 , which detect replicating SARS - CoV - 2 RNA in epithelial cells ( 7 , 54 , 55 ) , drive 425 macrophage anti - viral responses . Macrophage - derived interferon critically orchestrates the 426 anti - viral immune response to limit disease in other respiratory viral infections ( e . g . , 427 Newcastle Disease Virus , Respiratory Syncytial Virus ) ( 17 , 18 ) . We speculate that interferon 428 produced by ACE2 - positive macrophages via cell - intrinsic sensing may also contribute to 429 early control of SARS - CoV - 2 infection in the lung . Alternatively , this same macrophage - 430 derived interferon could contribute to disease pathology ( 56 , 57 ) . 431 432 In addition to cytosolic PRRs that detect serious threats , macrophages are also equipped with 433 PRRs at other subcellular locations ( e . g . , cell surface , endosomes ) to detect moderate threats . 434 14 This ‘cell extrinsic’ sensing detects neighboring infected cells , viral pathogen - associated 435 molecular patterns ( PAMPs ) , or host danger - associated molecular patterns ( DAMPs ) in the 436 extracellular milieu ( 58 ) . We and others ( 24 , 25 ) find that HMDM do not sense SARS - CoV - 437 2 , either at the cell surface or in endosomes , to trigger pro - inflammatory responses ( Fig . 5 ) , 438 which contradicts reports that SARS - CoV - 2 selectively induces a pro - inflammatory response 439 ( e . g . , TNF , IL - 6 , CXCL10 ) from HMDM ( 12 , 13 , 23 ) . Differences in viral stock preparation 440 or quantification could underpin these divergent observations . SARS - CoV - 2 is usually 441 cultured in cell lines ( e . g . , VERO E6 or Calu - 3 cells ( 12 ) ) that inherently respond to infection 442 by producing cytokines or undergoing cell death . Indeed , virus is often harvested at a time 443 point when a visible cytopathic effect emerges . Individual viral preparations quantified for 444 intact virions by TCID 50 or plaque assays may also contain free viral RNA , viral proteins , 445 non - infectious virions , and parental cell line - derived DAMPs and cytokines ( 59 ) . Thus , 446 published macrophage responses to viral preparations could represent an indirect response to 447 epithelial DAMPs or free viral PAMPs . Nevertheless , our viral stocks did not trigger cytokine 448 release from HMDM or THP - 1 cells in the absence of ACE2 , indicating that ACE - dependent 449 entry and early - stage replication are necessary for macrophage sensing ( Fig . 5A , 5B , Fig . 450 6A ) . We anticipate this observation will also apply to ACE2 - dependent SARS - CoV - 2 451 variants , including Omicron ( BA . 4 and BA . 5 lineages ) and , indeed , any beta - coronaviruses 452 that utilize ACE2 . Consistent with this , SARS - CoV - 1 , which also requires ACE2 for entry , 453 does not trigger macrophage cytokine responses ( 60 ) . 454 455 This study reveals that human macrophages do not sense SARS - CoV - 2 unless they express 456 ACE2 and support new viral synthesis . Our findings give new insight into SARS - CoV - 2 cell 457 tropism and the influence therein of macrophage innate immune pathways . Such studies of 458 innate immune cell - intrinsic and - extrinsic SARS - CoV - 2 recognition and response will help 459 reveal novel therapeutic targets for new drugs that dampen pathogenic pro - inflammatory 460 signaling in virulent viral infections without impeding host anti - viral defense . 461 462 MATERIALS AND METHODS 463 Re - analysis of human lung scRNA - seq 464 We reanalyzed three lung scRNA - seq datasets representing 1 ) samples from control or 465 COVID - 19 - infected individuals ( 27 ) , 2 ) samples from COVID - 19 - infected individuals ( 20 ) , 466 and 3 ) samples from control individuals ( 28 ) . 467 468 15 To compare matched cell types across datasets , we used Seurat v 4 . 1 . 1 ( 61 ) integration and 469 label transfer analysis to impose the ‘fine level’ cell identities defined by Melms et al . onto 470 the remaining datasets . We first applied the Seurat CCA integration pipeline to integrate the 471 individuals from Melms et al . before label transfer analysis . Functions NormalizeData and 472 FindVariableFeatures were run on each individual , and SelectIntegrationFeatures was run 473 with nfeatures set to 1000 . FindIntegrationAnchors and IntegrateData , followed by 474 ScaleData , and RunPCA , were all run with default parameters . We then transferred the cell 475 type identities from Melms et al . to the remaining datasets using the FindTransferAnchors 476 and TransferData functions with dims = 1 : 50 . 477 478 Reagents and inhibitors 479 Low molecular weight Poly I : C ( Invivogen , tlrl - picw ) was transfected into cells with 480 lipofectamine LTX ( Thermofisther , A12621 ) at 0 . 5 μ g pIC per well , while R848 Resiquimod 481 ( Miltenyi Biotech , 130 - 109 - 376 ) was used at a final concentration of 250 ng / ml . The TBK1 482 inhibitor BX - 795 ( Sigma - Aldrich , SML0694 ) was used at a final concentration of 5 μ M . 483 Remdesivir ( Gilead ) at a final concentration of 10 μ M . 484 485 Cells 486 Peripheral blood mononuclear cells were isolated from buffy coats by density centrifugation 487 using Ficoll - Paque Plus ( GE Healthcare ) . CD14 + monocytes were subsequently isolated 488 using magnetic - activated cell sorting ( Miltenyi Biotech ) according to the manufacturer’s 489 instructions . Human macrophages were differentiated from human CD14 + monocytes as 490 previously described ( 62 ) and then used for experiments on day 7 of differentiation . Human 491 monocyte - derived macrophages ( HMDMs ) were cultured in media consisting of RPMI 1640 492 medium ( Life Technologies ) supplemented with 10 % heat - inactivated fetal bovine serum 493 ( FBS ) , 2 mM GlutaMAX ( Life Technologies ) , 50 U / ml penicillin - streptomycin ( Life 494 Technologies ) and 150 ng / ml recombinant human macrophage colony - stimulating factor 495 ( CSF - 1 , endotoxin - free , expressed and purified by the University of Queensland Protein 496 Expression Facility ) . HMDM were seeded 16 h prior to experiments at 500 000 cells per well 497 in 12 - well plates or 200 000 cells per well in 24 - well plates . Studies using primary human 498 cells were approved by the University of Queensland Human Medical Research Ethics 499 Committee . THP - 1 cells ( TIB - 202 ; ATCC ) were maintained in RPMI 1640 medium 500 supplemented with 10 % heat - inactivated fetal bovine serum ( FBS ) , 2 mM GlutaMAX ( Life 501 16 Technologies ) and 50 U / ml penicillin - streptomycin . For experiments , THP - 1 cells were 502 seeded at 500 000 cells per well of a 12 - well plate and differentiated for 48 h with 30 ng / ml 503 phorbol - myristate - acetate ( PMA ) . Calu - 3 cells purchased from ATCC ( HTB - 55 ) were 504 maintained in Minimal Essential Media ( Invitrogen ) containing 10 % heat - inactivated fetal 505 bovine serum ( Cytiva ) , 50 U / ml penicillin , and streptomycin ( Life Technologies Australia ) , 506 and then seeded at 300 000 cells per well in 12 - well plates 48 h prior to experiments . A549 507 cells ( provided by Dr . Chris Macmillan , SCMB , UQ ) were maintained in Dulbecco’s 508 Modified Essential Medium ( DMEM ; Invitrogen ) supplemented with 10 % heat - inactivated 509 FBS and 50 U / ml penicillin - streptomycin . 510 511 Patient bronchoalveolar lavage ( BAL ) was obtained at the time of diagnostic bronchoscopy 512 as previously described ( 63 ) . Briefly , the bronchoscope was wedged into a non - dependent 513 sub - segmental bronchus ( 64 ) of a radiologically normal segment of the lung , and 20 ml of 514 normal saline was instilled , retrieved , and then discarded to clear the bronchoscope of 515 bronchial secretions . A further 80 - 100 ml was instilled in 20 ml aliquots and retrieved via 516 hand aspiration of the syringe . Studies using primary human cells were approved by the 517 Royal Melbourne Hospital and the University of Melbourne Human Research Ethics 518 Committees . BAL was filtered , and cells were washed and seeded at 1x10 6 cells per ml 519 overnight in 48 - well tissue culture plates in RPMI 1640 medium supplemented with 10 % 520 heat - inactivated fetal bovine serum ( FBS ) , two mM GlutaMAX ( Life Technologies ) and 50 521 U / ml penicillin - streptomycin ( Life Technologies ) . Non - adherent cells were removed via 522 media change four hours post - seeding , resulting in a > 90 % macrophage population , as 523 described previously ( 65 ) . 524 525 Lentiviral transduction 526 A lentiviral construct containing human ACE2 ( Addgene 155295 ) or mScarlet ( Addgene 527 85044 ) was cloned into pLV - CMV - MCS - IRES - Puro - Sin ( 66 ) and packaged into lentivirus in 528 HEK - 293T cells using third - generation lentiviral packaging plasmids ( 67 ) . Lentivirus - 529 containing supernatant was harvested on days 2 and 3 after transfection and then concentrated 530 using a Lenti - X concentrator ( Clontech , 631232 ) . HEK - 293T cells were transfected with the 531 expression vectors according to the manufacturer’s protocol with PEI 2500 ( BioScientific ) , 532 then transduced target THP - 1 cells were selected with puromycin ( 1 μ g / mL ) after 24 h and 533 used for assays after 72 h . 534 17 535 Viruses and cell infections 536 SARS - CoV - 2 isolate hCoV - 19 / Australia / QLD02 / 2020 was provided by Queensland Health 537 Forensic & Scientific Services , Queensland Department of Health . Virus was grown on Vero 538 E6 TMPRSS2 cells for 48 h in DMEM with 2 % FBS , and cell debris was cleared by 539 centrifugation at 500G for 5 minutes at room temperature . Virus was titered as described 540 previously by plaque assay ( 32 ) . Sanger sequencing was used to confirm that no mutations 541 occurred in the spike gene relative to the original clinical isolate . Cells ( HMDM , THP - 1 , 542 Calu - 3 ) in 12 - well plates ( 500 000 cells / well ) were challenged for 1 h at 37°C and 5 % CO 2 543 with 2 . 5 x 10 6 plaque - forming units ( PFUs ) for MOI 5 , or 2 . 5 x 10 5 PFUs for MOI 0 . 5 . For 544 Calu - 3 cells , virus was added to cells for a total volume of 500 μ L of RPMI 1640 with 2 % 545 FBS ( HMDM and THP - 1 ) or MEM with 2 % FBS ( Calu - 3 ) per well . The viral inoculum was 546 removed , and the medium was replaced with DMEM ( Invitrogen ) or MEM ( Invitrogen ) 547 containing 2 % FBS . Alternatively , virus was not removed from the cells . All studies with 548 SARS - CoV - 2 were performed under physical containment 3 ( PC3 ) conditions and were 549 approved by The University of Queensland Biosafety Committee ( IBC / 374B / SCMB / 2020 , 550 IBC / 518B / IMB / SCMB / 2022 ) and the University of Melbourne Institutional Biosafety 551 Committee in consultation with the Doherty Institute High Containment Facility 552 Management Group . 553 554 For studies involving SARS - CoV - 2 infection of BAL macrophages , the SARS - CoV - 2 isolate 555 hCoV - 19 / Australia / VIC01 / 2020 ( kindly provided by the Victorian Infectious Diseases 556 Reference Laboratory ) was grown in Vero cells for 72 h in serum - free MEM with 1 μ g / ml 557 TPCK trypsin . The median tissue culture infectious dose ( TCID 50 ) was calculated using the 558 Reed - Muench method . BAL macrophages ( approx . 2 . 5 x 10 5 cells ) were seeded overnight in 559 48 - well plates . Macrophages were infected with SARS - CoV - 2 ( MOI 1 ) in serum - free media 560 ( RPMI supplemented as described above ) for 1 h . The inoculum was removed , and cells were 561 washed before the media was replaced with 400 μ l serum - free media for a further 2 to 48 h . 562 VERO control cells were infected at an MOI of 0 . 5 , and maintenance media included 1 μ g / ml 563 of TPCK trypsin . RNA from cell - free supernatant was collected and extracted using a 564 QIAamp Viral RNA Mini Kit ( Qiagen ) , while RNA from cell monolayers was extracted 565 using the Rneasy Plus Mini Kit ( Qiagen ) . 566 567 18 Cell Death 568 THP - 1 were seeded at 50 000 cells per well of a black - walled , clear - bottomed 96 - well plate 569 ( CLS3916 , Corning ) . After 48 h of differentiation with PMA , cells were inoculated with 570 virus at MOI 5 and incubated for one h before the media was replaced with 100 μ l of fresh 571 RPMI with 2 % FCS . After 72 h , ~ 60 μ l of media was removed per well , and 30 μ l of ATPlite 572 substrate solution ( Perkin Elmer ) was added to the remaining 30 μ l . After 10 minutes of 573 incubation at room temperature , plates were sealed with Optical Adhesive Film 574 ( Thermofisher ) , and luminescence was read on a Victor Nivo Plate Reader ( Perkin Elmer ) . 575 576 RNA extraction and qPCR analysis 577 Cells were lysed in Buffer RLT plus β - mercaptoethanol , and the RNA was directly processed 578 using a Rneasy Mini Kit ( Qiagen ) with on - column DNase digestion according to the 579 manufacturer’s instructions . RNA concentration was measured using a NanoDrop 580 spectrophotometer , with equal starting concentrations of RNA for each sample used for 581 reverse transcription . Reverse transcription was performed using Superscript III Reverse 582 Transcriptase ( ThermoFisher ) with random hexamer priming . Quantitative PCR was 583 performed using SYBR green reagent ( Applied Biosystems ) on a QuantStudio 7 Flex Real - 584 Time PCR System ( ThermoFisher ) in 384 - well plates ( Applied Biosystems ) , and relative 585 gene expression was determined using the change - in - threshold ( 2 - ΔΔ CT ) method , using 586 Hypoxanthine Phosphoribosyltransferase 1 ( HPRT ) as an endogenous control . Alternatively , 587 gene expression was determined relative to a standard curve generated from plasmids 588 containing SARS - CoV - 2 Main Protease ( Mpro ) . Primers are as follows : HPRT F : 589 TCAGGCAGTATAATCCAAAGATGGT R : AGTCTGGCTTATATCCAACACTTCG ; 590 ACE2 F : TCACGATTGTTGGGACTCTGC , R : TCGCTTCATCTCCCACCACT ; IL6 F : 591 CTCAGCCCTGAGAAAGGAGACAT , R : TCAGCCATCTTTGGAAGGTTCA ; TNF F : 592 TGCCTGCTGCACTTTGGAGTGA , R : AGATGATCTGACTGCCTGGGCCAG ; IL1B F : 593 GAAGCTGATGGCCCTAAACA , R : AAGCCCTTGCTGTAGTGGTG , IFNB1 F : 594 CAGTCCTGGAAGAAAAACTGGAGA , R : TTGGCCTTCAGGTAATGCAGAA ; CXCL10 595 F : TGAAAGCAGTTAGCAAGGAAAGGT , R : AGCCTCTGTGTGGTCCATCC ; IFNL1 F : 596 CGCCTTGGAAGAGTCACTCA , R : GAAGCCTCAGGTCCCAATTC ; SARS - CoV - 2 Mpro 597 F : GAGACAGGTGGTTTCTCAATCG , R : ACGGCAATTCCAGTTTGAGC ; SARS - CoV - 2 598 E gene F : ACAGGTACGTTAATAGTTAATAGCGT , R : 599 19 ATATTGCAGCAGTACGCACACA . Subgenomic E gene : F : 600 AATATTGCAGCAGTACGCACACA , R : CGATCTCTTGTAGATCTGTTCTC 601 602 603 Copy number of the SARS - CoV - 2 E gene was measured in BAL or VERO cellular RNA 604 ( equal starting concentration of RNA ) and in RNA from cell culture media ( equal starting 605 volume ) . SensiFAST™ Probe Lo - ROX One - Step Kit with E - specific probe ( FAM - 606 ACACTAGCCATCCTTACTGCGCTTCG - QQA ) was used to detect the E gene , and a 607 plasmid - based standard curve was used to quantify the number of E copies . The following 608 primers were used to amplify the Mpro sequence from cDNA with the Phusion polymerase 609 kit ( New England BioLabs ) . F : AATAAGGTACCAGTGGTTTTAGAAAAATGG , 610 R : TTATTGCGGCCGCTCATTGGAAAGTAACACC . 611 The Mpro expression vector was generated by cloning the Mpro PCR product into a 612 modified pEF6 plasmid , with an HA - tag N - terminal of the multiple cloning site , by standard 613 restriction digest cloning techniques . The vector and correct insertion of Mpro were verified 614 by Sanger sequencing . 615 616 Cytokine analysis 617 Cytokine titers were determined using an AlphaLISA Immunoassay kit ( Perkin Elmer ) 618 according to the manufacturer’s instructions and analyzed on a Victor Nivo Plate Reader 619 ( Perkin Elmer ) . 620 621 Immunofluorescence 622 Cells were cultured on 12 mm glass coverslips and washed with PBS + / + ( PBS supplemented 623 with 1mM CaCl2 and 0 . 5mM MgCl2 , fixed for 30 min in 4 % paraformaldehyde ( Sigma 624 Aldrich ) , and blocked and permeabilized for 30 min with 3 % BSA , 0 . 3 % Triton X - 100 625 ( Sigma Aldrich ) at room temperature . Primary antibodies were incubated in 1 . 5 % BSA for 626 1 . 5 h at room temperature , and secondary antibodies conjugated to Alexa fluorophores 627 ( Invitrogen ) were incubated in 1 . 5 % BSA for 60 min in the dark at room temperature . Cells 628 were stained with Phalloidin ( PHDN1 - A ; Jomar Life Research ) and NP primary nanobody . 629 NP primary nanobody was kindly supplied by Dr . Ariel Isaacs , Watterson Laboratory , School 630 of Chemistry and Molecular Biology , UQ , QLD . After each incubation , cells were washed 3x 631 with PBS + / + and mounted with ProlongGold + DAPI solution ( Cell Signaling Technologies ) 632 onto glass slides . Z - stack image acquisition was performed on a confocal laser scanning 633 20 microscope ( Zeiss LSM880 ) using a 40x NA 1 . 3 water immersion objective or 20x NA 0 . 8 634 objective . Raw images were processed and analyzed using Fiji ( v1 . 53q ) . Images were batch 635 processed using a custom - made FIJI script ( 68 ) . The image processing included background 636 subtraction and median filtering ; then , the threshold was determined using the MinError 637 filter . The holes were filled in the binary image , and Analyze Particles was used to detect and 638 count nuclei and infected cells . Figures were prepared using Adobe Illustrator . For 639 quantification analysis , five random regions of interest ( ROIs ) per group were acquired . 640 641 642 Electron Microscopy 643 Electron microscopy samples were processed using a method adapted from a previous study 644 ( 69 ) . Briefly , cells were fixed in 2 . 5 % glutaraldehyde ( Electron Microscopy Services ) in PBS 645 for 24 h , then post - fixed in 1 % osmium ( ProSciTech ) for one h and contrasted with 1 % 646 aqueous uranyl acetate ( Electron Microscopy Services ) for one h . Samples were then serially 647 dehydrated in increasing percentages of ethanol before serial infiltration with LX - 112 resin 648 ( Ladd Research ) in a Biowave microwave ( Pelco ) . Ultrathin sections were obtained using an 649 ultramicrotome ( UC6 : Leica ) and further contrasted using Reynold lead post - stain . 650 Micrographs were acquired using a JEOL 1011 transmission electron microscope at 80 kV , 651 with a Morada CCD camera ( Olympus ) utilizing iTEM software . 652 653 Immunoblotting 654 For total cell lysates , cells were washed once with PBS and lysed with RIPA buffer ( 50 mM 655 Tris , 150 mM NaCl , one mM EDTA , 1 % Triton X - 100 , 0 . 1 % SDS , 1 % sodium deoxycholate , 656 protease inhibitor , pH 8 . 0 ) . A Pierce BCA protein assay kit ( Thermo Scientific ) was used to 657 equalize protein amounts , wherein SDS sample buffer containing 100 mM DTT ( Astral 658 Scientific ) was added , and samples were boiled at 95°C for 10 min to denature proteins . 659 Proteins were then separated on 4 - 15 % mini protean TGX precast gels ( Bio - Rad ) in running 660 buffer ( 200 mM glycine , 25 mM Tris , 0 . 1 % SDS ( pH8 . 6 ) ) , transferred to PVDF or 661 nitrocellulose membrane ( Bio - Rad 1620112 ) in blot buffer ( 48 nM Tris , 39 nM glycine , 662 0 . 04 % SDS , 20 % MeOH ) and subsequently blocked with 5 % ( w / v ) milk powder or BSA in 663 Tris - buffered saline with Tween - 20 ( TBST ) for 30 min . Primary antibodies were incubated 664 overnight at 4 deg C , followed by secondary antibodies linked to horseradish peroxidase 665 ( HRP ) ( Cell Signalling ) or AlexaFluor647 ( Invitrogen ) , and after each step , immunoblots 666 were washed 3x with TBST . HRP signals were visualized by enhanced chemiluminescence 667 21 ( ECL ) ( Bio - Rad ) and imaged with a Vilber Fusion Imaging system ( Vilber ) . The 668 fluorescence signal was detected using the AI600 imager ( Amersham ) . The following 669 antibodies were used : SARS - CoV - 2 Nucleoprotein ( Sino Biological ) , Tubulin ( 9F3 ; Cell 670 Signalling Technology ) , ACE2 ( AF933 ; RnD Systems ) , TMPRSS2 ( Abcam ) and Actin 671 ( 8H10D10 ; Cell Signalling Technology ) , ACE2 ( MA532307 , Invitrogen ) , Calnexin 672 ( ab22595 , Abcam ) . 673 674 Statistical Analysis : 675 Statistics were calculated using GraphPad Prism using tests as indicated in figure legends . 676 677 Supplementary Materials 678 679 Figure S1 : Re - analysis of macrophage ACE2 expression in vivo 680 Figure S2 : SARS - CoV - 2 does not replicate in HMDM 681 Figure S3 : SARS - CoV - 2 replicates in ACE2 - A549 cells 682 Figure S4 : Macrophage ACE2 expression potentiates macrophage inflammatory responses to 683 SARS - CoV - 2 at MOI 0 . 5 684 Figure S5 : BX - 795 blocks anti - viral cytokine induction in THP1 - ACE2 cells . 685 686 687 22 REFERENCES 688 689 1 . M . Hoffmann , H . Kleine - Weber , S . Schroeder , M . A . Mü , C . Drosten , S . Pö , N . Krü , T . 690 Herrler , S . Erichsen , T . S . Schiergens , G . Herrler , N . - H . Wu , A . Nitsche , S . Pö Hlmann , 691 SARS - CoV - 2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a 692 Clinically Proven Protease Inhibitor Article SARS - CoV - 2 Cell Entry Depends on ACE2 693 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor . Cell . 181 , 1 – 694 10 ( 2020 ) . 695 2 . C . B . Jackson , M . Farzan , B . Chen , H . Choe , Mechanisms of SARS - CoV - 2 entry into 696 cells . Nat . Rev . Mol . Cell Biol . 0123456789 ( 2021 ) , doi : 10 . 1038 / s41580 - 021 - 00418 - x . 697 3 . P . V’kovski , A . Kratzel , S . Steiner , H . Stalder , V . Thiel , Coronavirus biology and 698 replication : implications for SARS - CoV - 2 . Nat . Rev . Microbiol . 19 , 155 – 170 ( 2021 ) . 699 4 . B . Meng , A . Abdullahi , I . A . T . M . Ferreira , N . Goonawardane , A . Saito , I . Kimura , D . 700 Yamasoba , P . P . Gerber , S . Fatihi , S . Rathore , S . K . Zepeda , G . Papa , S . A . Kemp , T . 701 Ikeda , M . Toyoda , T . S . Tan , J . Kuramochi , S . Mitsunaga , T . Ueno , K . Shirakawa , A . 702 Takaori - Kondo , T . Brevini , D . L . Mallery , O . J . Charles , CITIID - NIHR BioResource 703 COVID - Collaboration , Genotype to Phenotype Japan ( GP - Japan ) Consortium 704 members , Ecuador - COVID19 Consortium , J . E . Bowen , A . Joshi , A . C . Walls , L . 705 Jackson , D . Martin , K . G . C . Smith , J . Bradley , J . A . G . Briggs , J . Choi , E . Madissoon , 706 K . Meyer , P . Mlcochova , L . Ceron - Gutierrez , R . Doffinger , S . A . Teichmann , A . J . 707 Fisher , M . S . Pizzuto , A . de Marco , D . Corti , M . Hosmillo , J . H . Lee , L . C . James , L . 708 Thukral , D . Veesler , A . Sigal , F . Sampaziotis , I . G . Goodfellow , N . J . Matheson , K . 709 Sato , R . K . Gupta , Altered TMPRSS2 usage by SARS - CoV - 2 Omicron impacts tropism 710 and fusogenicity . Nature ( 2022 ) , doi : 10 . 1038 / s41586 - 022 - 04474 - x . 711 5 . Y . J . Hou , K . Okuda , C . E . Edwards , D . R . Martinez , K . H . Dinnon , T . Kato , R . E . Lee , 712 B . L . Yount , T . M . Mascenik , G . Chen , K . N . Olivier , A . Ghio , V . Longping , S . R . 713 Leist , L . E . Gralinski , A . Schäfer , H . Dang , S . Nakano , L . Sun , M . L . Fulcher , A . 714 Livraghi - butrico , N . I . Nicely , M . Cameron , C . Cameron , D . J . Kelvin , A . De , D . M . 715 Margolis , A . Markmann , L . Bartelt , R . Zumwalt , J . Martinez , S . P . Salvatore , A . 716 Borczuk , P . R . Tata , A . Kimple , I . Jaspers , W . K . O . Neal , S . H . Randell , C . Richard , R . 717 S . Baric , SARS - CoV - 2 Reverse Genetics Reveals a Variable Infection Gradient in the 718 Respiratory Tract . Cell ( 2020 ) , doi : 10 . 1016 / j . cell . 2020 . 05 . 042 . 719 6 . D . Blanco - Melo , B . E . Nilsson - Payant , W . - C . Liu , S . Uhl , D . Hoagland , R . Møller , T . 720 X . Jordan , K . Oishi , M . Panis , D . Sachs , T . T . Wang , R . E . Schwartz , J . K . Lim , R . A . 721 Albrecht , B . R . Tenoever , Imbalanced host response to SARS - CoV - 2 drives 722 development of COVID - 19 . Cell , 1 – 10 ( 2020 ) . 723 7 . L . G . Thorne , A . Reuschl , L . Zuliani (cid:0) Alvarez , M . V . X . Whelan , J . Turner , M . 724 Noursadeghi , C . Jolly , G . J . Towers , SARS (cid:0) CoV (cid:0) 2 sensing by RIG (cid:0) I and MDA5 725 links epithelial infection to macrophage inflammation . EMBO J . , 1 – 17 ( 2021 ) . 726 8 . P . Bost , A . Giladi , Y . Liu , Y . Bendjelal , G . Xu , E . David , R . Blecher - Gonen , M . Cohen , 727 C . Medaglia , H . Li , A . Deczkowska , S . Zhang , B . Schwikowski , Z . Zhang , I . Amit , 728 Host - viral infection maps reveal signatures of severe COVID - 19 patients . Cell ( 2020 ) , 729 doi : 10 . 1016 / j . cell . 2020 . 05 . 006 . 730 23 9 . R . L . Chua , S . Lukassen , S . Trump , B . P . Hennig , D . Wendisch , F . Pott , O . Debnath , L . 731 Thürmann , F . Kurth , M . T . Völker , J . Kazmierski , B . Timmermann , S . Twardziok , S . 732 Schneider , F . Machleidt , H . Müller - Redetzky , M . Maier , A . Krannich , S . Schmidt , F . 733 Balzer , J . Liebig , J . Loske , N . Suttorp , J . Eils , N . Ishaque , U . G . Liebert , C . von Kalle , 734 A . Hocke , M . Witzenrath , C . Goffinet , C . Drosten , S . Laudi , I . Lehmann , C . Conrad , L . 735 E . Sander , R . Eils , COVID - 19 severity correlates with airway epithelium – immune cell 736 interactions identified by single - cell analysis . Nat . Biotechnol . 38 , 970 – 979 ( 2020 ) . 737 10 . R . Knoll , J . L . Schultze , J . Schulte - Schrepping , Monocytes and Macrophages in 738 COVID - 19 . Front . Immunol . 12 , 1 – 12 ( 2021 ) . 739 11 . M . Merad , J . C . Martin , Pathological inflammation in patients with COVID - 19 : a key 740 role for monocytes and macrophages . Nat . Rev . Immunol . 20 , 355 – 362 ( 2020 ) . 741 12 . J . Zheng , Y . Wang , K . Li , D . K . Meyerholz , C . Allamargot , S . Perlman , Severe Acute 742 Respiratory Syndrome Coronavirus 2 - Induced Immune Activation and Death of 743 Monocyte - Derived Human Macrophages and Dendritic Cells . J . Infect . Dis . 223 , 785 – 744 795 ( 2021 ) . 745 13 . D . Yang , H . Chu , Y . Hou , Y . Chai , H . Shuai , A . C . Y . Lee , X . Zhang , Y . Wang , B . Hu , 746 X . Huang , T . T . T . Yuen , J . P . Cai , J . Zhou , S . Yuan , A . J . Zhang , J . F . W . Chan , K . Y . 747 Yuen , Attenuated interferon and proinflammatory response in SARS - CoV - 2 - infected 748 human dendritic cells is associated with viral antagonism of STAT1 phosphorylation . J . 749 Infect . Dis . 222 , 734 – 745 ( 2020 ) . 750 14 . K . R . Short , A . G . Brooks , P . C . Reading , S . L . Londrigan , The fate of influenza A virus 751 after infection of human macrophages and dendritic cells . J . Gen . Virol . 93 , 2315 – 2325 752 ( 2012 ) . 753 15 . J . E . Gern , E . C . Dick , W . M . Lee , S . Murray , K . Meyer , Z . T . Handzel , W . W . Busse , 754 Rhinovirus enters but does not replicate inside monocytes and airway macrophages . J . 755 Immunol . Baltim . Md 1950 . 156 , 621 – 7 ( 1996 ) . 756 16 . S . L . Londrigan , L . M . Wakim , J . Smith , A . J . Haverkate , A . G . Brooks , P . C . Reading , 757 IFITM3 and type I interferons are important for the control of influenza A virus 758 replication in murine macrophages . Virology . 540 , 17 – 22 ( 2020 ) . 759 17 . M . Goritzka , S . Makris , F . Kausar , L . R . Durant , C . Pereira , Y . Kumagai , F . J . Culley , 760 M . Mack , S . Akira , C . Johansson , Alveolar macrophage - derived type I interferons 761 orchestrate innate immunity to RSV through recruitment of antiviral monocytes . J . Exp . 762 Med . 212 , 699 – 714 ( 2015 ) . 763 18 . Y . Kumagai , O . Takeuchi , H . Kato , H . Kumar , K . Matsui , E . Morii , K . Aozasa , T . 764 Kawai , S . Akira , Alveolar Macrophages Are the Primary Interferon - α Producer in 765 Pulmonary Infection with RNA Viruses . Immunity . 27 , 240 – 252 ( 2007 ) . 766 19 . C . Schneider , S . P . Nobs , A . K . Heer , M . Kurrer , G . Klinke , N . van Rooijen , J . Vogel , 767 M . Kopf , Alveolar Macrophages Are Essential for Protection from Respiratory Failure 768 and Associated Morbidity following Influenza Virus Infection . PLoS Pathog . 10 ( 2014 ) , 769 doi : 10 . 1371 / journal . ppat . 1004053 . 770 24 20 . T . M . Delorey , C . G . K . Ziegler , G . Heimberg , R . Normand , Y . Yang , Å . Segerstolpe , 771 D . Abbondanza , S . J . Fleming , A . Subramanian , D . T . Montoro , K . A . Jagadeesh , K . K . 772 Dey , P . Sen , M . Slyper , Y . H . Pita - Juárez , D . Phillips , J . Biermann , Z . Bloom - 773 Ackermann , N . Barkas , A . Ganna , J . Gomez , J . C . Melms , I . Katsyv , E . Normandin , P . 774 Naderi , Y . V . Popov , S . S . Raju , S . Niezen , L . T . - Y . Tsai , K . J . Siddle , M . Sud , V . M . 775 Tran , S . K . Vellarikkal , Y . Wang , L . Amir - Zilberstein , D . S . Atri , J . Beechem , O . R . 776 Brook , J . Chen , P . Divakar , P . Dorceus , J . M . Engreitz , A . Essene , D . M . Fitzgerald , R . 777 Fropf , S . Gazal , J . Gould , J . Grzyb , T . Harvey , J . Hecht , T . Hether , J . Jané - Valbuena , 778 M . Leney - Greene , H . Ma , C . McCabe , D . E . McLoughlin , E . M . Miller , C . Muus , M . 779 Niemi , R . Padera , L . Pan , D . Pant , C . Pe’er , J . Pfiffner - Borges , C . J . Pinto , J . Plaisted , J . 780 Reeves , M . Ross , M . Rudy , E . H . Rueckert , M . Siciliano , A . Sturm , E . Todres , A . 781 Waghray , S . Warren , S . Zhang , D . R . Zollinger , L . Cosimi , R . M . Gupta , N . Hacohen , 782 H . Hibshoosh , W . Hide , A . L . Price , J . Rajagopal , P . R . Tata , S . Riedel , G . Szabo , T . L . 783 Tickle , P . T . Ellinor , D . Hung , P . C . Sabeti , R . Novak , R . Rogers , D . E . Ingber , Z . G . 784 Jiang , D . Juric , M . Babadi , S . L . Farhi , B . Izar , J . R . Stone , I . S . Vlachos , I . H . Solomon , 785 O . Ashenberg , C . B . M . Porter , B . Li , A . K . Shalek , A . - C . Villani , O . Rozenblatt - Rosen , 786 A . Regev , COVID - 19 tissue atlases reveal SARS - CoV - 2 pathology and cellular targets . 787 Nature . 595 , 107 – 113 ( 2021 ) . 788 21 . T . T . - H . Wu , K . J . Travaglini , A . Rustagi , D . Xu , Y . Zhang , S . K . Jang , A . Gillich , R . 789 Dehghannasiri , G . Martinez - Colon , A . Beck , A . J . Wilk , M . Morri , W . L . Trope , J . B . 790 Shrager , S . R . Quake , C . S . Kuo , J . Salzman , P . S . Kim , C . A . Blish , M . A . Krasnow , 791 bioRxiv , in press , doi : 10 . 1101 / 2022 . 05 . 10 . 491266 . 792 22 . E . Sefik , R . Qu , C . Junqueira , E . Kaffe , H . Mirza , J . Zhao , J . R . Brewer , A . Han , H . R . 793 Steach , B . Israelow , H . N . Blackburn , S . E . Velazquez , Y . G . Chen , S . Halene , A . 794 Iwasaki , E . Meffre , M . Nussenzweig , J . Lieberman , C . B . Wilen , Y . Kluger , R . A . 795 Flavell , Inflammasome activation in infected macrophages drives COVID - 19 pathology . 796 Nature . 606 , 585 – 593 ( 2022 ) . 797 23 . M . M . Abdelmoaty , P . Yeapuri , J . Machhi , K . E . Olson , F . Shahjin , V . Kumar , Y . Zhou , 798 J . Liang , K . Pandey , A . Acharya , S . N . Byrareddy , R . L . Mosley , H . E . Gendelman , 799 Defining the Innate Immune Responses for SARS - CoV - 2 - Human Macrophage 800 Interactions . Front . Immunol . 12 , 1 – 15 ( 2021 ) . 801 24 . L . Dalskov , M . Møhlenberg , J . Thyrsted , J . Blay (cid:0) Cadanet , E . T . Poulsen , B . H . 802 Folkersen , S . H . Skaarup , D . Olagnier , L . Reinert , J . J . Enghild , H . J . Hoffmann , C . K . 803 Holm , R . Hartmann , SARS (cid:0) CoV (cid:0) 2 evades immune detection in alveolar 804 macrophages . EMBO Rep . 21 , 1 – 10 ( 2020 ) . 805 25 . M . A . Niles , P . Gogesch , S . Kronhart , S . Ortega Iannazzo , G . Kochs , Z . Waibler , M . 806 Anzaghe , Macrophages and Dendritic Cells Are Not the Major Source of Pro - 807 Inflammatory Cytokines Upon SARS - CoV - 2 Infection . Front . Immunol . 12 , 1 – 12 808 ( 2021 ) . 809 26 . Q . Lu , J . Liu , S . Zhao , M . F . Gomez Castro , M . Laurent - Rolle , J . Dong , X . Ran , P . 810 Damani - Yokota , H . Tang , T . Karakousi , J . Son , M . E . Kaczmarek , Z . Zhang , S . T . 811 Yeung , B . T . McCune , R . E . Chen , F . Tang , X . Ren , X . Chen , J . C . C . Hsu , M . Teplova , 812 B . Huang , H . Deng , Z . Long , T . Mudianto , S . Jin , P . Lin , J . Du , R . Zang , T . T . Su , A . 813 Herrera , M . Zhou , R . Yan , J . Cui , J . Zhu , Q . Zhou , T . Wang , J . Ma , S . B . Koralov , Z . 814 Zhang , I . Aifantis , L . N . Segal , M . S . Diamond , K . M . Khanna , K . A . Stapleford , P . 815 25 Cresswell , Y . Liu , S . Ding , Q . Xie , J . Wang , SARS - CoV - 2 exacerbates 816 proinflammatory responses in myeloid cells through C - type lectin receptors and Tweety 817 family member 2 . Immunity . 54 , 1304 - 1319 . e9 ( 2021 ) . 818 27 . J . C . Melms , J . Biermann , H . Huang , Y . Wang , A . Nair , S . Tagore , I . Katsyv , A . F . 819 Rendeiro , A . D . Amin , D . Schapiro , C . J . Frangieh , A . M . Luoma , A . Filliol , Y . Fang , 820 H . Ravichandran , M . G . Clausi , G . A . Alba , M . Rogava , S . W . Chen , P . Ho , D . T . 821 Montoro , A . E . Kornberg , A . S . Han , M . F . Bakhoum , N . Anandasabapathy , M . Suárez - 822 Fariñas , S . F . Bakhoum , Y . Bram , A . Borczuk , X . V . Guo , J . H . Lefkowitch , C . Marboe , 823 S . M . Lagana , A . Del Portillo , E . J . Tsai , E . Zorn , G . S . Markowitz , R . F . Schwabe , R . 824 E . Schwartz , O . Elemento , A . Saqi , H . Hibshoosh , J . Que , B . Izar , A molecular single - 825 cell lung atlas of lethal COVID - 19 . Nature . 595 , 114 – 119 ( 2021 ) . 826 28 . E . Madissoon , A . Wilbrey - Clark , R . J . Miragaia , K . Saeb - Parsy , K . T . Mahbubani , N . 827 Georgakopoulos , P . Harding , K . Polanski , N . Huang , K . Nowicki - Osuch , R . C . 828 Fitzgerald , K . W . Loudon , J . R . Ferdinand , M . R . Clatworthy , A . Tsingene , S . van 829 Dongen , M . Dabrowska , M . Patel , M . J . T . Stubbington , S . A . Teichmann , O . Stegle , K . 830 B . Meyer , scRNA - seq assessment of the human lung , spleen , and esophagus tissue 831 stability after cold preservation . Genome Biol . 21 , 1 ( 2019 ) . 832 29 . C . Muus , M . D . Luecken , G . Eraslan , L . Sikkema , A . Waghray , G . Heimberg , Y . 833 Kobayashi , E . D . Vaishnav , A . Subramanian , C . Smillie , K . A . Jagadeesh , E . T . Duong , 834 E . Fiskin , E . Torlai Triglia , M . Ansari , P . Cai , B . Lin , J . Buchanan , S . Chen , J . Shu , A . 835 L . Haber , H . Chung , D . T . Montoro , T . Adams , H . Aliee , S . J . Allon , Z . Andrusivova , I . 836 Angelidis , O . Ashenberg , K . Bassler , C . Bécavin , I . Benhar , J . Bergenstråhle , L . 837 Bergenstråhle , L . Bolt , E . Braun , L . T . Bui , S . Callori , M . Chaffin , E . Chichelnitskiy , J . 838 Chiou , T . M . Conlon , M . S . Cuoco , A . S . E . Cuomo , M . Deprez , G . Duclos , D . Fine , D . 839 S . Fischer , S . Ghazanfar , A . Gillich , B . Giotti , J . Gould , M . Guo , A . J . Gutierrez , A . C . 840 Habermann , T . Harvey , P . He , X . Hou , L . Hu , Y . Hu , A . Jaiswal , L . Ji , P . Jiang , T . S . 841 Kapellos , C . S . Kuo , L . Larsson , M . A . Leney - Greene , K . Lim , M . Litvi ň uková , L . S . 842 Ludwig , S . Lukassen , W . Luo , H . Maatz , E . Madissoon , L . Mamanova , K . 843 Manakongtreecheep , S . Leroy , C . H . Mayr , I . M . Mbano , A . M . McAdams , A . N . 844 Nabhan , S . K . Nyquist , L . Penland , O . B . Poirion , S . Poli , C . Qi , R . Queen , D . Reichart , 845 I . Rosas , J . C . Schupp , C . V . Shea , X . Shi , R . Sinha , R . V . Sit , K . Slowikowski , M . 846 Slyper , N . P . Smith , A . Sountoulidis , M . Strunz , T . B . Sullivan , D . Sun , C . Talavera - 847 López , P . Tan , J . Tantivit , K . J . Travaglini , N . R . Tucker , K . A . Vernon , M . H . 848 Wadsworth , J . Waldman , X . Wang , K . Xu , W . Yan , W . Zhao , C . G . K . Ziegler , Single - 849 cell meta - analysis of SARS - CoV - 2 entry genes across tissues and demographics . Nat . 850 Med . 27 , 546 – 559 ( 2021 ) . 851 30 . M . Magnen , R . You , A . A . Rao , R . T . Davis , L . Rodriguez , C . R . Simoneau , L . Hysenaj , 852 K . H . Hu , T . U . C . Consortium , C . Love , P . G . Woodruff , D . J . Erle , C . M . 853 Hendrickson , C . S . Calfee , M . A . Matthay , J . P . Roose , A . Sil , M . Ott , C . R . Langelier , 854 M . F . Krummel , M . R . Looney , Immediate myeloid depot for SARS - CoV - 2 in the 855 human lung ( 2022 ) , p . 2022 . 04 . 28 . 489942 , , doi : 10 . 1101 / 2022 . 04 . 28 . 489942 . 856 31 . C . Blériot , S . Chakarov , F . Ginhoux , Determinants of Resident Tissue Macrophage 857 Identity and Function . Immunity . 52 , 957 – 970 ( 2020 ) . 858 32 . L . Schimmel , K . Y . Chew , C . J . Stocks , T . E . Yordanov , P . Essebier , A . Kulasinghe , J . 859 Monkman , A . F . R . Santos Miggiolaro , C . Cooper , L . Noronha , K . Schroder , A . K . 860 26 Lagendijk , L . I . Labzin , K . R . Short , E . J . Gordon , Endothelial cells are not productively 861 infected by SARS (cid:0) CoV (cid:0) 2 . Clin . Transl . Immunol . 10 , 1 – 18 ( 2021 ) . 862 33 . S . Jalloh , J . Olejnik , J . Berrigan , A . Nisa , E . L . Suder , H . Akiyama , M . Lei , S . 863 Ramaswamy , S . Tyagi , Y . Bushkin , E . Mühlberger , S . Gummuluru , CD169 - mediated 864 restrictive SARS - CoV - 2 infection of macrophages induces pro - inflammatory responses . 865 PLOS Pathog . 18 , e1010479 ( 2022 ) . 866 34 . L . I . Labzin , M . Bottermann , P . Rodriguez - Silvestre , S . Foss , J . T . Andersen , M . 867 Vaysburd , D . Clift , L . C . James , Antibody and DNA sensing pathways converge to 868 activate the inflammasome during primary human macrophage infection . EMBO J . 38 , 869 e101365 ( 2019 ) . 870 35 . S . S . Diebold , T . Kaisho , H . Hemmi , S . Akira , C . Reis E Sousa , Innate Antiviral 871 Responses by Means of TLR7 - Mediated Recognition of Single - Stranded RNA . Science . 872 303 , 1529 – 1531 ( 2004 ) . 873 36 . M . Weber , A . Gawanbacht , M . Habjan , A . Rang , C . Borner , A . M . Schmidt , S . 874 Veitinger , R . Jacob , S . Devignot , G . Kochs , A . García - Sastre , F . Weber , Incoming RNA 875 virus nucleocapsids containing a 5 ′ - triphosphorylated genome activate RIG - I and 876 antiviral signaling . Cell Host Microbe . 13 , 336 – 346 ( 2013 ) . 877 37 . C . Lucas , P . Wong , J . Klein , T . B . R . Castro , J . Silva , M . Sundaram , M . K . Ellingson , T . 878 Mao , J . E . Oh , B . Israelow , T . Takahashi , M . Tokuyama , P . Lu , A . Venkataraman , A . 879 Park , S . Mohanty , H . Wang , A . L . Wyllie , C . B . F . Vogels , R . Earnest , S . Lapidus , I . M . 880 Ott , A . J . Moore , M . C . Muenker , J . B . Fournier , M . Campbell , C . D . Odio , A . 881 Casanovas - Massana , A . Obaid , A . Lu - Culligan , A . Nelson , A . Brito , A . Nunez , A . 882 Martin , A . Watkins , B . Geng , C . Kalinich , C . Harden , C . Todeasa , C . Jensen , D . Kim , 883 D . McDonald , D . Shepard , E . Courchaine , E . B . White , E . Song , E . Silva , E . Kudo , G . 884 DeIuliis , H . Rahming , H . J . Park , I . Matos , J . Nouws , J . Valdez , J . Fauver , J . Lim , K . A . 885 Rose , K . Anastasio , K . Brower , L . Glick , L . Sharma , L . Sewanan , L . Knaggs , M . 886 Minasyan , M . Batsu , M . Petrone , M . Kuang , M . Nakahata , M . Campbell , M . Linehan , 887 M . H . Askenase , M . Simonov , M . Smolgovsky , N . Sonnert , N . Naushad , P . 888 Vijayakumar , R . Martinello , R . Datta , R . Handoko , S . Bermejo , S . Prophet , S . 889 Bickerton , S . Velazquez , T . Alpert , T . Rice , W . Khoury - Hanold , X . Peng , Y . Yang , Y . 890 Cao , Y . Strong , R . Herbst , A . C . Shaw , R . Medzhitov , W . L . Schulz , N . D . Grubaugh , 891 C . Dela Cruz , S . Farhadian , A . I . Ko , S . B . Omer , A . Iwasaki , Longitudinal analyses 892 reveal immunological misfiring in severe COVID - 19 . Nature . 584 , 463 – 469 ( 2020 ) . 893 38 . M . Koutsakos , L . C . Rowntree , L . Hensen , B . Y . Chua , C . E . van de Sandt , J . R . Habel , 894 W . Zhang , X . Jia , L . Kedzierski , T . M . Ashhurst , G . H . Putri , F . Marsh - Wakefield , M . 895 N . Read , D . N . Edwards , E . B . Clemens , C . Y . Wong , F . L . Mordant , J . A . Juno , F . 896 Amanat , J . Audsley , N . E . Holmes , C . L . Gordon , O . C . Smibert , J . A . Trubiano , C . M . 897 Hughes , M . Catton , J . T . Denholm , S . YC . Tong , D . L . Doolan , T . C . Kotsimbos , D . C . 898 Jackson , F . Krammer , D . I . Godfrey , A . W . Chung , N . JC . King , S . R . Lewin , A . K . 899 Wheatley , S . J . Kent , K . Subbarao , J . McMahon , I . Thevarajan , T . HO . Nguyen , A . C . 900 Cheng , K . Kedzierska , Integrated immune dynamics define correlates of COVID - 19 901 severity and antibody responses . Cell Rep . Med . , 100208 ( 2021 ) . 902 27 39 . L . I . Labzin , M . A . R . Lauterbach , E . Latz , Interferons and inflammasomes : 903 Cooperation and counterregulation in disease . J . Allergy Clin . Immunol . 138 , 37 – 46 904 ( 2016 ) . 905 40 . G . Kokic , H . S . Hillen , D . Tegunov , C . Dienemann , F . Seitz , J . Schmitzova , L . Farnung , 906 A . Siewert , C . Höbartner , P . Cramer , Mechanism of SARS - CoV - 2 polymerase stalling 907 by remdesivir . Nat . Commun . 12 , 279 ( 2021 ) . 908 41 . C . Junqueira , Â . Crespo , S . Ranjbar , J . Ingber , B . Parry , S . Ravid , L . B . de Lacerda , M . 909 Lewandrowski , S . Clark , F . Ho , S . M . Vora , V . Leger , C . Beakes , J . Margolin , N . 910 Russell , L . Gehrke , U . Das Adhikari , L . Henderson , E . Janssen , D . Kwon , C . Sander , J . 911 Abraham , M . Filbin , M . B . Goldberg , H . Wu , G . Mehta , S . Bell , A . E . Goldfeld , J . 912 Lieberman , SARS - CoV - 2 infects blood monocytes to activate NLRP3 and AIM2 913 inflammasomes , pyroptosis and cytokine release . MedRxiv Prepr . Serv . Health Sci . 914 ( 2021 ) , doi : 10 . 1101 / 2021 . 03 . 06 . 21252796 . 915 42 . J . W . Schoggins , Interferon - stimulated genes : Roles in viral pathogenesis . Curr . Opin . 916 Virol . 6 , 40 – 46 ( 2014 ) . 917 43 . K . Clark , L . Plater , M . Peggie , P . Cohen , Use of the pharmacological inhibitor BX795 918 to study the regulation and physiological roles of TBK1 and I κ B Kinase ∈ : A distinct 919 upstream kinase mediates ser - 172 phosphorylation and activation . J . Biol . Chem . 284 , 920 14136 – 14146 ( 2009 ) . 921 44 . S . Beyerstedt , E . B . Casaro , É . B . Rangel , COVID - 19 : angiotensin - converting enzyme 2 922 ( ACE2 ) expression and tissue susceptibility to SARS - CoV - 2 infection . Eur . J . Clin . 923 Microbiol . Infect . Dis . 40 , 905 – 919 ( 2021 ) . 924 45 . S . Joshi , H . Wollenzien , E . Leclerc , Y . P . Jarajapu , Hypoxic regulation of angiotensin - 925 converting enzyme 2 and Mas receptor in human CD34 + cells . J . Cell . Physiol . 234 , 926 20420 – 20431 ( 2019 ) . 927 46 . T . H . Beacon , G . P . Delcuve , J . R . Davie , Epigenetic regulation of ACE2 , the receptor 928 of the SARS - CoV - 2 virus . Genome . 64 , 386 – 399 ( 2021 ) . 929 47 . C . Junqueira , Â . Crespo , S . Ranjbar , L . B . de Lacerda , M . Lewandrowski , J . Ingber , B . 930 Parry , S . Ravid , S . Clark , M . R . Schrimpf , F . Ho , C . Beakes , J . Margolin , N . Russell , K . 931 Kays , J . Boucau , U . Das Adhikari , S . M . Vora , V . Leger , L . Gehrke , L . A . Henderson , 932 E . Janssen , D . Kwon , C . Sander , J . Abraham , M . B . Goldberg , H . Wu , G . Mehta , S . 933 Bell , A . E . Goldfeld , M . R . Filbin , J . Lieberman , Fc γ R - mediated SARS - CoV - 2 infection 934 of monocytes activates inflammation . Nature . 606 ( 2022 ) , doi : 10 . 1038 / s41586 - 022 - 935 04702 - 4 . 936 48 . Q . Zhang , P . Bastard , Z . Liu , J . Le Pen , M . Moncada - Velez , J . Chen , M . Ogishi , I . K . D . 937 Sabli , S . Hodeib , C . Korol , J . Rosain , K . Bilguvar , J . Ye , A . Bolze , B . Bigio , R . Yang , 938 A . A . Arias , Q . Zhou , Y . Zhang , F . Onodi , S . Korniotis , L . Karpf , Q . Philippot , M . 939 Chbihi , L . Bonnet - Madin , K . Dorgham , N . Smith , W . M . Schneider , B . S . Razooky , H . - 940 H . Hoffmann , E . Michailidis , L . Moens , J . E . Han , L . Lorenzo , L . Bizien , P . Meade , A . - 941 L . Neehus , A . C . Ugurbil , A . Corneau , G . Kerner , P . Zhang , F . Rapaport , Y . 942 Seeleuthner , J . Manry , C . Masson , Y . Schmitt , A . Schlüter , T . Le Voyer , T . Khan , J . Li , 943 J . Fellay , L . Roussel , M . Shahrooei , M . F . Alosaimi , D . Mansouri , H . Al - Saud , F . Al - 944 28 Mulla , F . Almourfi , S . Z . Al - Muhsen , F . Alsohime , S . Al Turki , R . Hasanato , D . van de 945 Beek , A . Biondi , L . R . Bettini , M . D’Angio , P . Bonfanti , L . Imberti , A . Sottini , S . 946 Paghera , E . Quiros - Roldan , C . Rossi , A . J . Oler , M . F . Tompkins , C . Alba , I . 947 Vandernoot , J . - C . Goffard , G . Smits , I . Migeotte , F . Haerynck , P . Soler - Palacin , A . 948 Martin - Nalda , R . Colobran , P . - E . Morange , S . Keles , F . Çölkesen , T . Ozcelik , K . K . 949 Yasar , S . Senoglu , Ş . N . Karabela , C . R . Gallego , G . Novelli , S . Hraiech , Y . Tandjaoui - 950 Lambiotte , X . Duval , C . Laouénan , A . L . Snow , C . L . Dalgard , J . Milner , D . C . Vinh , T . 951 H . Mogensen , N . Marr , A . N . Spaan , B . Boisson , S . Boisson - Dupuis , J . Bustamante , A . 952 Puel , M . Ciancanelli , I . Meyts , T . Maniatis , V . Soumelis , A . Amara , M . Nussenzweig , 953 A . García - Sastre , F . Krammer , A . Pujol , D . Duffy , R . Lifton , S . - Y . Zhang , G . 954 Gorochov , V . Béziat , E . Jouanguy , V . Sancho - Shimizu , C . M . Rice , L . Abel , L . D . 955 Notarangelo , A . Cobat , H . C . Su , J . - L . Casanova , Inborn errors of type I IFN immunity 956 in patients with life - threatening COVID - 19 . Science . 28 , eabd4570 ( 2020 ) . 957 49 . P . Bastard , A . Gervais , T . Le Voyer , J . Rosain , Q . Philippot , J . Manry , E . Michailidis , 958 H . Hoffmann , S . Eto , M . Garcia - Prat , L . Bizien , A . Parra - Martínez , R . Yang , L . 959 Haljasmägi , M . Migaud , K . Särekannu , J . Maslovskaja , N . de Prost , Y . Tandjaoui - 960 Lambiotte , C . - E . Luyt , B . Amador - Borrero , A . Gaudet , J . Poissy , P . Morel , P . Richard , 961 F . Cognasse , J . Troya , S . Trouillet - Assant , A . Belot , K . Saker , P . Garçon , J . G . Rivière , 962 J . - C . Lagier , S . Gentile , L . B . Rosen , E . Shaw , T . Morio , J . Tanaka , D . Dalmau , P . - L . 963 Tharaux , D . Sene , A . Stepanian , B . Megarbane , V . Triantafyllia , A . Fekkar , J . R . Heath , 964 J . L . Franco , J . - M . Anaya , J . Solé - Violán , L . Imberti , A . Biondi , P . Bonfanti , R . 965 Castagnoli , O . M . Delmonte , Y . Zhang , A . L . Snow , S . M . Holland , C . Biggs , M . 966 Moncada - Vélez , A . A . Arias , L . Lorenzo , S . Boucherit , B . Coulibaly , D . Anglicheau , A . 967 M . Planas , F . Haerynck , S . Duvlis , R . L . Nussbaum , T . Ozcelik , S . Keles , A . A . 968 Bousfiha , J . El Bakkouri , C . Ramirez - Santana , S . Paul , Q . Pan - Hammarström , L . 969 Hammarström , A . Dupont , A . Kurolap , C . N . Metz , A . Aiuti , G . Casari , V . Lampasona , 970 F . Ciceri , L . A . Barreiros , E . Dominguez - Garrido , M . Vidigal , M . Zatz , D . van de Beek , 971 S . Sahanic , I . Tancevski , Y . Stepanovskyy , O . Boyarchuk , Y . Nukui , M . Tsumura , L . 972 Vidaur , S . G . Tangye , S . Burrel , D . Duffy , L . Quintana - Murci , A . Klocperk , N . Y . 973 Kann , A . Shcherbina , Y . - L . Lau , D . Leung , M . Coulongeat , J . Marlet , R . Koning , L . F . 974 Reyes , A . Chauvineau - Grenier , F . Venet , G . Monneret , M . C . Nussenzweig , R . 975 Arrestier , I . Boudhabhay , H . Baris - Feldman , D . Hagin , J . Wauters , I . Meyts , A . H . 976 Dyer , S . P . Kennelly , N . M . Bourke , R . Halwani , N . S . Sharif - Askari , K . Dorgham , J . 977 Sallette , S . M . Sedkaoui , S . AlKhater , R . Rigo - Bonnin , F . Morandeira , L . Roussel , D . C . 978 Vinh , S . R . Ostrowski , A . Condino - Neto , C . Prando , A . Bonradenko , A . N . Spaan , L . 979 Gilardin , J . Fellay , S . Lyonnet , K . Bilguvar , R . P . Lifton , S . Mane , M . S . Anderson , B . 980 Boisson , V . Béziat , S . - Y . Zhang , E . Vandreakos , O . Hermine , A . Pujol , P . Peterson , T . 981 H . Mogensen , L . Rowen , J . Mond , S . Debette , X . de Lamballerie , X . Duval , F . Mentré , 982 M . Zins , P . Soler - Palacin , R . Colobran , G . Gorochov , X . Solanich , S . Susen , J . 983 Martinez - Picado , D . Raoult , M . Vasse , P . K . Gregersen , L . Piemonti , C . Rodríguez - 984 Gallego , L . D . Notarangelo , H . C . Su , K . Kisand , S . Okada , A . Puel , E . Jouanguy , C . M . 985 Rice , P . Tiberghien , Q . Zhang , A . Cobat , L . Abel , J . - L . Casanova , Autoantibodies 986 neutralizing type I IFNs are present in ~ 4 % of uninfected individuals over 70 years old 987 and account for ~ 20 % of COVID - 19 deaths . Sci . Immunol . 6 , eabl4340 ( 2021 ) . 988 50 . R . A . Grant , L . Morales - Nebreda , N . S . Markov , S . Swaminathan , M . Querrey , E . R . 989 Guzman , D . A . Abbott , H . K . Donnelly , A . Donayre , I . A . Goldberg , Z . M . Klug , N . 990 Borkowski , Z . Lu , H . Kihshen , Y . Politanska , L . Sichizya , M . Kang , A . Shilatifard , C . 991 Qi , J . W . Lomasney , A . C . Argento , J . M . Kruser , E . S . Malsin , C . O . Pickens , S . B . 992 29 Smith , J . M . Walter , A . E . Pawlowski , D . Schneider , P . Nannapaneni , H . Abdala - 993 Valencia , A . Bharat , C . J . Gottardi , G . R . S . Budinger , A . V . Misharin , B . D . Singer , R . 994 G . Wunderink , R . A . Grant , L . Morales - Nebreda , N . S . Markov , S . Swaminathan , M . 995 Querrey , E . R . Guzman , D . A . Abbott , H . K . Donnelly , A . Donayre , I . A . Goldberg , Z . 996 M . Klug , N . Borkowski , Z . Lu , H . Kihshen , Y . Politanska , L . Sichizya , M . Kang , A . 997 Shilatifard , C . Qi , J . W . Lomasney , A . C . Argento , J . M . Kruser , E . S . Malsin , C . O . 998 Pickens , S . B . Smith , J . M . Walter , A . E . Pawlowski , D . Schneider , P . Nannapaneni , H . 999 Abdala - Valencia , A . Bharat , C . J . Gottardi , G . R . S . Budinger , A . V . Misharin , B . D . 1000 Singer , R . G . Wunderink , A . A . Wagh , A . R . Hauser , A . R . Wolfe , A . Thakrar , A . V . 1001 Yeldandi , A . A . Wang , A . R . Levenson , A . M . Joudi , B . Tran , C . A . Gao , C . Kurihara , 1002 C . J . Schroedl , C . M . Horvath , D . Meza , D . D . Odell , D . W . Kamp , D . R . Winter , E . A . 1003 Ozer , E . D . Shanes , E . T . Bartom , E . J . Rendleman , E . M . Leibenguth , F . Wehbe , G . Y . 1004 Liu , G . T . Gadhvi , H . T . Navarro , J . I . Sznajder , J . E . Dematte , J . Le , J . M . Arnold , J . C . 1005 Du , J . Coleman , J . I . Bailey , J . S . Deters , J . A . Fiala , J . Starren , K . M . Ridge , K . 1006 Secunda , K . Aren , K . L . Gates , K . Todd , L . D . Gradone , L . N . Textor , L . F . Wolfe , L . L . 1007 Pesce , L . A . Nunes Amaral , M . L . Rosenbaum , M . Kandpal , M . Jain , M . A . Sala , M . 1008 Saine , M . Carns , M . J . Alexander , M . J . Cuttica , M . H . Prickett , N . H . Khan , N . S . 1009 Chandel , N . D . Soulakis , O . R . Rivas , P . C . Seed , P . A . Reyfman , P . D . Go , P . H . S . 1010 Sporn , P . R . Cooper , R . Tomic , R . Patel , R . Garza - Castillon , R . Kalhan , R . I . Morimoto , 1011 R . J . Mylvaganam , S . S . Kim , S . W . M . Gatesy , S . Thakkar , S . Ben Maamar , S . H . Han , 1012 S . R . Rosenberg , S . Nozick , S . J . Green , S . R . Russell , T . A . Poor , T . J . Zak , T . A . 1013 Lombardo , T . Stoeger , T . Shamaly , Z . Ren , Circuits between infected macrophages and 1014 T cells in SARS - CoV - 2 pneumonia . Nature . 590 , 635 – 641 ( 2021 ) . 1015 51 . P . Bost , A . Giladi , Y . Liu , Y . Bendjelal , G . Xu , E . David , R . Blecher - Gonen , M . Cohen , 1016 C . Medaglia , H . Li , A . Deczkowska , S . Zhang , B . Schwikowski , Z . Zhang , I . Amit , 1017 Host - viral infection maps reveal signatures of severe COVID - 19 patients . Cell , 1 – 14 1018 ( 2020 ) . 1019 52 . A . C . Salina , D . dos - Santos , T . S . Rodrigues , M . Fortes - Rocha , E . G . Freitas - Filho , D . 1020 L . Alzamora - Terrel , I . M . Castro , T . F . Fraga da Silva , M . H . de Lima , D . C . 1021 Nascimento , C . M . Silva , J . E . Toller - Kawahisa , A . Becerra , S . Oliveira , D . B . Caetité , 1022 L . Almeida , A . Y . Ishimoto , T . M . Lima , R . B . Martins , F . Veras , N . B . do Amaral , M . 1023 C . Giannini , L . P . Bonjorno , M . I . Lopes , M . N . Benatti , S . S . Batah , R . C . Santana , F . 1024 C . Vilar , M . A . Martins , R . L . Assad , S . C . de Almeida , F . R . de Oliveira , E . Arruda 1025 Neto , T . M . Cunha , J . C . Alves - Filho , V . L . Bonato , F . Q . Cunha , A . T . Fabro , H . I . 1026 Nakaya , D . S . Zamboni , P . Louzada - Junior , R . D . Oliveira , L . D . Cunha , Efferocytosis 1027 of SARS - CoV - 2 - infected dying cells impairs macrophage anti - inflammatory functions 1028 and clearance of apoptotic cells . eLife . 11 , e74443 ( 2022 ) . 1029 53 . M . Zheng , R . Karki , E . P . Williams , D . Yang , E . Fitzpatrick , P . Vogel , C . B . Jonsson , T . 1030 D . Kanneganti , TLR2 senses the SARS - CoV - 2 envelope protein to produce 1031 inflammatory cytokines . Nat . Immunol . 22 , 829 – 838 ( 2021 ) . 1032 54 . A . Rebendenne , A . L . Chaves Valadão , M . Tauziet , G . Maarifi , B . Bonaventure , J . 1033 McKellar , R . Planès , S . Nisole , M . Arnaud - Arnould , O . Moncorgé , C . Goujon , SARS - 1034 CoV - 2 Triggers an MDA - 5 - Dependent Interferon Response Which Is Unable To 1035 Control Replication in Lung Epithelial Cells . J . Virol . 95 , e02415 - 20 ( 2021 ) . 1036 30 55 . N . G . Sampaio , L . Chauveau , J . Hertzog , A . Bridgeman , G . Fowler , J . P . Moonen , M . 1037 Dupont , R . A . Russell , M . Noerenberg , J . Rehwinkel , The RNA sensor MDA5 detects 1038 SARS - CoV - 2 infection . Sci . Rep . 11 , 13638 ( 2021 ) . 1039 56 . A . Broggi , S . Ghosh , B . Sposito , R . Spreafico , F . Balzarini , A . Lo Cascio , N . Clementi , 1040 M . de Santis , N . Mancini , F . Granucci , I . Zanoni , Type III interferons disrupt the lung 1041 epithelial barrier upon viral recognition . Science . 369 , 706 – 712 ( 2020 ) . 1042 57 . J . Major , S . Crotta , M . Llorian , T . M . McCabe , H . H . Gad , S . L . Priestnall , R . 1043 Hartmann , A . Wack , Type I and III interferons disrupt lung epithelial repair during 1044 recovery from viral infection . Science . 369 , 712 – 717 ( 2020 ) . 1045 58 . A . Iwasaki , P . S . Pillai , Innate immunity to influenza virus infection . Nat . Rev . Immunol . 1046 14 , 315 – 328 ( 2014 ) . 1047 59 . Q . Niu , L . Ma , S . Zhu , L . Li , Q . Zheng , J . Hou , H . Lian , L . Wu , X . Yan , Quantitative 1048 Assessment of the Physical Virus Titer and Purity by Ultrasensitive Flow Virometry . 1049 Angew . Chem . - Int . Ed . 60 , 9351 – 9356 ( 2021 ) . 1050 60 . O . García - Nicolás , P . V’kovski , F . Zettl , G . Zimmer , V . Thiel , A . Summerfield , No 1051 Evidence for Human Monocyte - Derived Macrophage Infection and Antibody - Mediated 1052 Enhancement of SARS - CoV - 2 Infection . Front . Cell . Infect . Microbiol . 11 , 1 – 10 1053 ( 2021 ) . 1054 61 . Y . Hao , S . Hao , E . Andersen - Nissen , W . M . Mauck , S . Zheng , A . Butler , M . J . Lee , A . 1055 J . Wilk , C . Darby , M . Zager , P . Hoffman , M . Stoeckius , E . Papalexi , E . P . Mimitou , J . 1056 Jain , A . Srivastava , T . Stuart , L . M . Fleming , B . Yeung , A . J . Rogers , J . M . McElrath , 1057 C . A . Blish , R . Gottardo , P . Smibert , R . Satija , Integrated analysis of multimodal single - 1058 cell data . Cell . 184 , 3573 - 3587 . e29 ( 2021 ) . 1059 62 . R . C . Coll , J . R . Hill , C . J . Day , A . Zamoshnikova , D . Boucher , N . L . Massey , J . L . 1060 Chitty , J . A . Fraser , M . P . Jennings , A . A . B . Robertson , K . Schroder , MCC950 directly 1061 targets the NLRP3 ATP - hydrolysis motif for inflammasome inhibition . Nat . Chem . Biol . 1062 15 , 556 – 559 ( 2019 ) . 1063 63 . E . Tsantikos , M . Lau , C . M . N . Castelino , M . J . Maxwell , S . L . Passey , M . J . Hansen , N . 1064 E . McGregor , N . A . Sims , D . P . Steinfort , L . B . Irving , G . P . Anderson , M . L . Hibbs , 1065 Granulocyte - CSF links destructive inflammation and comorbidities in obstructive lung 1066 disease . J . Clin . Invest . 128 , 2406 – 2418 ( 2018 ) . 1067 64 . N . Radhakrishna , M . Farmer , D . P . Steinfort , P . King , A Comparison of Techniques for 1068 Optimal Performance of Bronchoalveolar Lavage . J . Bronchol . Interv . Pulmonol . 22 , 1069 300 – 305 ( 2015 ) . 1070 65 . J . Q . Davies , S . Gordon , " Isolation and Culture of Human Macrophages BT - Basic 1071 Cell Culture Protocols " in , C . D . Helgason , C . L . Miller , Eds . ( Humana Press , Totowa , 1072 NJ , 2005 ) , pp . 105 – 116 . 1073 66 . L . Schimmel , M . van der Stoel , C . Rianna , A . M . van Stalborch , A . de Ligt , M . 1074 Hoogenboezem , S . Tol , J . van Rijssel , R . Szulcek , H . J . Bogaard , P . Hofmann , R . Boon , 1075 M . Radmacher , V . de Waard , S . Huveneers , J . D . van Buul , Stiffness - Induced 1076 31 Endothelial DLC - 1 Expression Forces Leukocyte Spreading through Stabilization of the 1077 ICAM - 1 Adhesome . Cell Rep . 24 , 3115 – 3124 ( 2018 ) . 1078 67 . T . Dull , R . Zufferey , M . Kelly , R . J . Mandel , M . Nguyen , D . Trono , L . Naldini , A 1079 Third - Generation Lentivirus Vector with a Conditional Packaging System . J . Virol . 72 , 1080 8463 – 8471 ( 1998 ) . 1081 68 . J . Schindelin , I . Arganda - Carreras , E . Frise , V . Kaynig , M . Longair , T . Pietzsch , S . 1082 Preibisch , C . Rueden , S . Saalfeld , B . Schmid , J . - Y . Tinevez , D . J . White , V . 1083 Hartenstein , K . Eliceiri , P . Tomancak , A . Cardona , Fiji : an open - source platform for 1084 biological - image analysis . Nat . Methods . 9 , 676 – 682 ( 2012 ) . 1085 69 . M . T . Howes , M . Kirkham , J . Riches , K . Cortese , P . J . Walser , F . Simpson , M . M . Hill , 1086 A . Jones , R . Lundmark , M . R . Lindsay , D . J . Hernandez - Deviez , G . Hadzic , A . 1087 McCluskey , R . Bashir , L . Liu , P . Pilch , H . McMahon , P . J . Robinson , J . F . Hancock , S . 1088 Mayor , R . G . Parton , Clathrin - independent carriers form a high capacity endocytic 1089 sorting system at the leading edge of migrating cells . J . Cell Biol . 190 , 675 – 691 ( 2010 ) . 1090 1091 1092 32 ACKNOWLEDGEMENTS 1093 We gratefully acknowledge Dr . Lilian Schimmel for producing the ACE2 and mScarlet 1094 expressing lentiviruses , Dr . Ariel Isaacs for producing the anti - N nanobody , and Dr . Fiona 1095 Wylie for critical reading of this manuscript . This work was supported by National Health 1096 and Medical Research Council ( NHMRC ) of Australia funding , including fellowships 1097 ( 1124612 to LL ; 1177174 to K . Subbarao ; 1156489 to RGP ; 2009075 to K . Schroder ) and 1098 grants ( 2010757 to LL and EG ; 2013574 to CMN , 1140064 and 1150083 to RGP ; 2007979 1099 to KRS ; 1184532 to SL ; 2009677 to K . Schroder ) and the Doherty Institute COVID - 19 1100 Agility Fund . The Melbourne WHO Collaborating Centre for Reference and Research on 1101 Influenza is supported by the Australian Government Department of Health . 1102 1103 COMPETING INTERESTS : 1104 KRS is a consultant for Sanofi , Roche , and NovoNordisk . K . Schroder is a co - inventor on 1105 patent applications for NLRP3 inhibitors licensed to Inflazome Ltd , a company 1106 headquartered in Dublin , Ireland . Inflazome is developing drugs that target the NLRP3 1107 inflammasome to address unmet clinical needs in inflammatory disease . K . Schroder served 1108 on the Scientific Advisory Board of Inflazome in 2016 – 2017 and serves as a consultant to 1109 Quench Bio , USA , and Novartis , Switzerland . 1110 1111 AUTHOR CONTRIBUTIONS 1112 Conception : LIL and SLL 1113 Data acquisition and analysis : LIL , KYC , KE , XW , TE , CJS , JR , RP , HM , BH , TY , CLH , SE , 1114 SF , FLM , DPS , CMN , AKL , EG , RGP , SLL 1115 Funding acquisition : LIL , SLL , K . Schroder 1116 Manuscript original draft : LIL , K . Schroder 1117 Manuscript editing : LIL , K . Subbarao , KRS , SLL , K . Schroder 1118 1119 DATA AND MATERIALS AVAILABILITY : All data are available in the main text or the 1120 supplementary materials . 1121 1122 33 FIGURE LEGENDS 1123 1124 Figure 1 : ACE2 is not expressed on HMDM or BAL but can be ectopically expressed in 1125 THP - 1 cells . 1126 A : HMDM and THP - 1 cells were analyzed by qPCR for ACE2 mRNA expression , 1127 with each data point showing an independent donor or experiment ( n = 3 ) . B : HMDM 1128 were stimulated with IFN β ( 10 ng / ml ) for six h , and protein extracts were analyzed by 1129 immunoblot alongside extracts from THP - 1 cells ( WT , THP - 1 - ACE2 , THP - 1 - mSc ) . 1130 C : BAL macrophages from 3 donors were adhered overnight and lysed . The 1131 expression of ACE2 in BAL macrophages was analyzed by immunoblot relative to 1132 loading control ( Calnexin ) . Lysate from A549 cells overexpressing ACE2 was used as 1133 a positive control . 1134 1135 Figure 2 : ACE2 - negative HMDM and BAL do not support SARS - CoV - 2 entry or early - 1136 stage replication . 1137 A - B : Calu - 3 cells ( A , B ) or HMDM ( C , D ) were infected as indicated , and the virus 1138 was left on the cells . Viral RNA isolated from cells was measured by qPCR ( A , C ) , or 1139 viral protein by immunoblot ( B , D ) . Blots are representative of three independent 1140 experiments ( Calu - 3 ) or three independent donors ( HMDM ) . E - F : BAL macrophages 1141 ( MOI 1 ) or Vero cells ( MOI 0 . 5 ) were infected with SARS - CoV - 2 for one h before 1142 the virus was removed , and cell - associated viral RNA ( E ) or viral RNA released in 1143 cell - free supernatants ( F ) was analyzed by qPCR of SARS - CoV - 2 E gene at 2 - and 1144 48 - h post - infection . Data are mean + SEM , with each point representing an individual 1145 donor ( HMDM , BAL macrophages ; n = 5 ) or independent experiments ( Calu - 3 , 1146 VERO ; n = 2 - 3 ) . Asterisks indicate significance : p ≤ 0 . 05 ( * ) , p ≤ 0 . 001 ( * * ) , p ≤ 1147 0 . 0001 ( * * * ) ( two - way ANOVA , Tukey’s multiple comparison test ) . 1148 1149 Figure 3 : ACE2 - positive macrophages support SARS - CoV - 2 entry , early - stage 1150 replication and productive virion release . 1151 A - F : Cells were infected with SARS - CoV - 2 at MOI 0 . 5 or MOI 5 , as indicated . After 1152 one h , the virus inoculum was removed , cells were washed , and cells or supernatants 1153 were harvested at the indicated times ( 0 h = immediately after the virus inoculum was 1154 removed ) . Cellular viral mRNA was analyzed by qPCR ( A - B ) . Viral N protein at 24 h 1155 34 was assessed by immunofluorescence staining , scale bar = 30 μ m ( C ) , and quantified 1156 relative to the total number of cells ( D ) . Infectious virions released into cell 1157 supernatants were measured by plaque assay ( E - F ) . Data show the mean + SEM of 3 - 1158 8 independent experiments , with data points representing individual experiments . 1159 Asterisks indicate significance : p ≤ 0 . 05 ( * ) , p ≤ 0 . 001 ( * * ) , p ≤ 0 . 0001 ( * * * ) ( A - B , 1160 E - F : two - way ANOVA , Tukey’s multiple comparison test ; D : unpaired t - test , Holm - 1161 Šídák test ) . 1162 1163 Figure 4 : Macrophages can take up SARS - CoV - 2 independently of ACE2 1164 A - F : Transmission electron microscopy of indicated cells infected with SARS - CoV - 2 1165 ( MOI 20 ) at indicated time points . For low magnification images ( A , D ) scale bar = 1166 10 μ m , and for all other images ( B , C , E , F ) scale bar = 500 nm . 1167 1168 Figure 5 : SARS - CoV - 2 does not trigger inflammatory responses in ACE2 - negative 1169 HMDM 1170 A : HMDM were infected with SARS - CoV - 2 ( MOI 5 ) or stimulated with R848 or 1171 transfected pIC for 24 h . Cytokines in cell supernatants were analyzed by alphaLISA . 1172 Each data point represents an individual donor ( n = 6 - 15 ) . Graphs show mean + SEM , 1173 and significance is indicated by asterisks ( one - way ANOVA , Dunnett’s multiple 1174 comparison test ) . B : HMDM were challenged with SARS - CoV - 2 ( MOI 0 . 5 , 5 ) or 1175 transfected pI : C . Gene expression at 2 and 24 h was analyzed by qPCR . Graphs show 1176 mean + SEM , where each data point represents an individual donor ( n = 3 ) , and 1177 asterisks indicate significance : p ≤ 0 . 05 ( * ) , p ≤ 0 . 001 ( * * ) , p ≤ 0 . 0001 ( * * * ) ( two - 1178 way ANOVA , Dunnett’s multiple comparison test ) . 1179 1180 Figure 6 : ACE2 - positive macrophages sense entering or replicating SARS - CoV - 2 to 1181 drive pro - inflammatory and anti - viral responses 1182 A - C : THP - 1 - ACE - 2 and THP - 1 - mSc cells ( A , B ) or Calu - 3 cells ( C ) were infected 1183 with SARS - CoV - 2 at MOI 5 . Cells were harvested at the indicated times ( 0 h = 1184 immediately after the virus inoculum was removed ) , and gene expression was 1185 quantified by qPCR . Gene expression at each time point is presented relative to the 1186 mock control to show fold - gene induction . Data are mean + SEM of 4 independent 1187 experiments ( indicated by individual data points ) , and significance is indicated by 1188 35 asterisks : p ≤ 0 . 05 ( * ) , p ≤ 0 . 001 ( * * ) , p ≤ 0 . 0001 ( * * * ) ( two - way ANOVA , Tukey’s 1189 multiple comparison test ) . ( D - E ) . THP - 1 - ACE2 cells were infected with SARS - CoV - 1190 2 at MOI 5 in the presence of 10 μ m remdesivir , and viral RNA ( C ) or inflammatory 1191 cytokines ( D ) were measured at 24 h p . i . Data show mean + SEM of 3 independent 1192 experiments ( indicated by individual data points ) , and asterisks indicate significance : 1193 p ≤ 0 . 05 ( * ) , p ≤ 0 . 001 ( * * ) , p ≤ 0 . 0001 ( * * * ) ( two - way ANOVA , Sidak’s multiple 1194 comparison test ) . 1195 1196 Figure 7 : Blocking cytokine signaling in ACE2 - positive macrophages prolongs 1197 infectious virion release 1198 A : THP - 1 - ACE - 2 and THP - 1 - mSc cells were infected with SARS - CoV - 2 ( MOI 5 ) . 1199 Cell death was analyzed by ATPlite assay at 72 h . Data are presented as cell viability 1200 relative to mock infection and are mean + SEM of 3 independent experiments . 1201 Asterisks indicate significance : p ≤ 0 . 05 ( * ) , p ≤ 0 . 001 ( * * ) , p ≤ 0 . 0001 ( * * * ) ( two - 1202 way ANOVA , Tukey’s multiple comparison test ) . B : Schematic of TBK1 ( BX - 795 ) 1203 inhibition . C - E : THP - 1 - ACE - 2 or Calu - 3 cells were stimulated with SARS - CoV - 2 at 1204 MOI 5 . After one h , the viral inoculum was removed , and BX - 795 was added . 1205 Supernatants were harvested at 72 h , CXCL10 was analyzed by ELISA ( C ) and viral 1206 titers were analyzed by plaque assay ( D , E ) . Data show the mean + SEM of at least 1207 three independent experiments , with each data point representing a different 1208 experiment . Significance is indicated by asterisks : p ≤ 0 . 05 ( * ) , p ≤ 0 . 001 ( * * ) , p ≤ 1209 0 . 0001 ( * * * ) ( C : one - way ANOVA , Tukey’s multiple comparison test ; D , E : ratio - 1210 paired t - test ) . 1211 Figure 1 A B ACE2 120 Calnexin 70 A C E 2 - A 549 kDa BAL MF D1 D2 D3 C - + - + - + - + D1 D2 D3 D4 HMDM IFN β TMPRSS2 ACE2 50 120 100 W T A C E 2 m S c THP - 1 β - TUBULIN 50 H M D M T hp1 W T T hp1 A C E 2 T hp1 m S c 0 . 0 0 . 5 1 . 0 1 . 5 2 . 0 50010001500 A c e2 / H p r t Figure 2 Calu3 Calu3 BAL MF BAL MF VERO VERO Nucleo - protein Tubulin HMDM M o ck 2h 24h M o ck 2h 24h MOI 5 MOI 0 . 5 50 37 Nucleo - protein 50 Tubulin kDa A C 50 37 25 50 37 M o ck 2h 24h MOI 5 MOI 0 . 5 72h M o ck 2h 24h 72h kDa B D E F MOI 0 . 5 MOI 5 M o ck 2h24h M o ck 2h24h 10 0 10 1 10 2 10 3 10 4 10 5 10 6 M p r o C op i e s pe r μ g RN A * * HMDM MOI 0 . 5 MOI 5 M o ck 2h 24h M o ck 2h 24h 10 1 10 2 10 3 10 4 10 5 10 6 10 7 M p r o C op i e s pe r μ g RN A ns ns ns M o ck 2h 48h 10 2 10 3 10 4 10 5 10 6 10 7 E c op i e s pe r μ g RN A ns ns ns M o ck 2h 48h 10 2 10 3 10 4 10 5 10 6 10 7 10 8 10 9 E c op i e s pe r μ g RN A M o ck 2h 48h 10 2 10 3 10 4 10 5 10 6 10 7 E c op i e s pe r μ g R N A ns M o ck 2h 48h 10 2 10 3 10 4 10 5 10 6 10 7 10 8 10 9 E c op i e s pe r μ g R N A Cell - associated RNA Supernatant RNA Figure 3 A E B F MOI 5 hours p . i . ACE2 mSc Calu3 MOI 0 . 5 ACE2 mSc Calu3 hours p . i . MOI 5 ACE2 mSc Calu3 hours p . i . MOI 0 . 5 ACE2 mSc Calu3 hours p . i . 0 24 48 72 0 24 48 72 0 24 48 72 10 - 2 10 - 1 10 0 10 1 10 2 10 3 M p r o / H p r t 0 24 48 72 0 24 48 72 0 24 48 72 10 - 1 10 0 10 1 10 2 10 3 10 4 M p r o / H p r t M O I 5 T H P - 1 AC E 2 T H P - 1 m S C C D Dapi / NP / Phalloidin NP M o ck M O I 5 M o ck ACE2 mSc 0h 24h 0 5 10 15 20 25 % N P po s i t i v e c e ll s 7 8 0 24 48 72 0 24 48 72 0 24 48 72 10 0 10 1 10 2 10 3 10 4 10 5 10 6 1010 P F U / m l 0 2 4 4 8 7 2 0 2 4 4 8 7 2 0 2 4 4 8 7 2 10 0 10 1 10 2 10 3 10 4 10 5 10 6 10 7 10 8 P F U / m l PM Figure 4 HMDM 1h p . i . THP - 1 ACE2 1h p . i . THP - 1 ACE2 1h p . i . PM Calu3 72h p . i . HMDM 1h p . i . THP - 1 ACE2 1h p . i . B A C D E F Figure 5 A B F o l d i ndu c t i on r e l a t i v e t o m o ck Ifnb1 Ifnl1 Il6 Tnf Cxcl10 Il1b F o l d i ndu c t i on r e l a t i v e t o m o ck M o c k S A R S - C o V - 2 p I C 0 5 10 15 20 100 200 C X C L10 ng / m l ns M o c k S A R S - C o V - 2 R 848 0 1 2 3 450100150200 I L - 6 ng / m l ns M o c k S A R S - C o V - 2 R 84 8 0 20 40 60 T N F ng / m l ns M o ck M O I 0 . 5 M O I 5 p I C 0 5 10 15 10000200003000040000 2h 24h ns ns M o ck M O I 0 . 5 M O I 5 p I C 012345 50010001500 2h 24h ns M o ck M O I 0 . 5 M O I 5 p I C 0 10 20 30 40 50001000015000 2h 24h ns ns M o ck M O I 0 . 5 M O I 5 p I C 0 10 20 30 40 200 400 600 2h 24h M o ck M O I 0 . 5 M O I 5 p I C 0 5 10 20 25 2h 24h M o ck M O I 0 . 5 M O I 5 R 848 0 5 10 50010001500 2h 24h ns ns Figure 6 Ifnb1 Ifnl1 Cxcl10 Il6 Tnf Calu3 A B ACE2 mSc 0 24 48 72 0 5 10 15 hours p . i . F o l d i ndu c t i on r e l a t i v e t o m o ck ( 0h ) 0 24 48 72 0 20 40 60 80 hours p . i . 0 24 48 72 0 5 10 15 hours p . i . 0 24 48 72 0 2 4 6 hours p . i . 0 24 48 72 0 . 0 0 . 5 1 . 0 1 . 5 2 . 0 hours p . i . Ifnb1 Ifnl1 Cxcl10 Il6 Tnf 0 24 48 72 0 20 40 60 80 100 hours p . i . F o l d i ndu c t i on r e l a t i v e t o m o ck ( 0h ) 0 24 48 72 0 50 100 150 200 hours p . i . 0 24 48 72 0 1 2 3 4 hours p . i . 0 24 48 72 0 500 1000 1500 hours p . i . 0 24 48 72 0 100 200 300 hours p . i . MOI 5 MOI 5 Ifnb1 Ifnl1 Il6 Cxcl10 C D Tnf M o ck M O I 0 . 5 M O I 5 10 - 4 10 - 3 10 - 2 10 - 1 10 0 10 1 10 2 10 3 10 4 s g E / H p r t sgE M O I 0 . 5 M O I 5 0 100 200 300 400 F o l d i ndu c t i on r e l a t i v e t o m o ck M O I 0 . 5 M O I 5 0 20 40 60 80 M O I 0 . 5 M O I 5 0 10 000 20 000 30 000 M O I 0 . 5 M O I 5 0 5 10 15 M O I 0 . 5 M O I 5 0 500 1 000 1 500 2 000 2 500 PBS Remdesivir PBS Remdesivir 0 24 48 72 0 . 0 0 . 5 1 . 0 1 . 5 2 . 0 hours p . i . Il1b F o l d i ndu c t i on r e l a t i v e t o m o ck ( 0h ) ACE2 mSc MOI 5 THP - 1 - ACE2 E Figure 7 ACE2 mSc A B C D M o ck M O I 5 M O I 5 + B X 795 0 5 10 15 20 C X C L10 ng / m l M o ck M O I 0 . 5 M O I 5 0 20 40 60 80 100 120 % c e ll v i ab ili t y M O I 5 M O I 5 + B X 795 10 2 10 3 10 4 10 5 10 6 10 7 M O I 5 M O I 5 + B X 795 10 2 10 3 10 4 10 5 10 6 E RIG - I MDA5 TBK1 MAVS IRF3 P IFN β IFN β JAKSTAT ISGs Type 1 IFN Receptor Viral RNA BX - 795 P F U / m l P F U / m l THP - 1 ACE2 THP - 1 ACE2 Calu3